U.S. patent application number 10/360274 was filed with the patent office on 2004-01-08 for method for promoting hematopoietic and mesenchymal cell proliferation and differentiation.
This patent application is currently assigned to The University of Southern California. Invention is credited to diZerega, Gere S., Rodgers, Kathleen E..
Application Number | 20040006003 10/360274 |
Document ID | / |
Family ID | 27556310 |
Filed Date | 2004-01-08 |
United States Patent
Application |
20040006003 |
Kind Code |
A1 |
Rodgers, Kathleen E. ; et
al. |
January 8, 2004 |
Method for promoting hematopoietic and mesenchymal cell
proliferation and differentiation
Abstract
The present invention provides methods, improved cell culture
medium and kits for promoting hematopoietic and mesenchymal stem
and lineage-specific cell proliferation and differentiation by
growth in the presence of angiotensinogen, angiotensin I (AI), AI
analogues, AI fragments and analogues thereof, angiotensin II
(AII), AII analogues, AII fragments or analogues thereof or AII
AT.sub.2 type 2 receptor agonists, either alone or in combination
with other growth factors and cytokines.
Inventors: |
Rodgers, Kathleen E.; (Long
Beach, CA) ; diZerega, Gere S.; (Pasadena,
CA) |
Correspondence
Address: |
MCDONNELL BOEHNEN HULBERT & BERGHOFF
300 SOUTH WACKER DRIVE
SUITE 3200
CHICAGO
IL
60606
US
|
Assignee: |
The University of Southern
California
Los Angeles
CA
|
Family ID: |
27556310 |
Appl. No.: |
10/360274 |
Filed: |
February 7, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10360274 |
Feb 7, 2003 |
|
|
|
09716886 |
Nov 20, 2000 |
|
|
|
09716886 |
Nov 20, 2000 |
|
|
|
09012400 |
Jan 23, 1998 |
|
|
|
6335195 |
|
|
|
|
60036507 |
Jan 28, 1997 |
|
|
|
60046859 |
May 8, 1997 |
|
|
|
60063684 |
Oct 28, 1997 |
|
|
|
60063910 |
Oct 31, 1997 |
|
|
|
60065612 |
Nov 18, 1997 |
|
|
|
60066593 |
Nov 26, 1997 |
|
|
|
Current U.S.
Class: |
424/93.1 ;
514/7.9 |
Current CPC
Class: |
C12N 2501/39 20130101;
A61P 19/08 20180101; A61P 7/06 20180101; C12N 5/0634 20130101; C12N
5/0663 20130101; C12N 2502/11 20130101; A61P 35/00 20180101; C12N
5/0647 20130101; C12N 2501/32 20130101; A61K 48/00 20130101; C07K
7/14 20130101; A61P 7/00 20180101; A61K 38/085 20130101; A61P 43/00
20180101; C12N 2500/38 20130101; A61K 2035/124 20130101; C12N
5/0645 20130101 |
Class at
Publication: |
514/7 ; 514/14;
514/15 |
International
Class: |
A61K 038/10; A61K
038/08 |
Claims
We claim:
1. A method of accelerating the proliferation of mesenchymal stem
cells comprising contacting the mesenchymal stem cells with an
amount effective to accelerate proliferation of mesenchymal stem
cells of at least one active agent comprising a sequence consisting
of at least three contiguous amino acids of groups R.sup.1-R.sup.8
in the sequence of general formula I
R.sup.1--R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R-
.sup.7-R.sup.8 in which R.sup.1 and R.sup.2 together form a group
of formula X--R.sup.A--R.sup.B--, wherein X is H or a one to three
peptide group and a peptide bond between R.sup.A and R.sup.B is
labile to aminopeptidase A cleavage; R.sup.3 is selected from the
group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc
and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr, excluding sequences including R.sup.4 as a
terminal Tyr group.
2. A method of accelerating the proliferation of hematopoietic
lineage-specific cells comprising contacting the hematopoietic
lineage-specific cells with an amount effective to accelerate
proliferation of hematopoietic lineage-specific cells of at least
one active agent comprising a sequence consisting of at least three
contiguous amino acids of groups R.sup.1-R.sup.8 in the sequence of
general formula I R.sup.1--R.sup.2--R.sup.3--R.sup.4
--R.sup.5--R.sup.6--R.sup.7-R.sup.8 in which R.sup.1 R.sup.2
together form a group of formula X--R.sup.A--R.sup.B--, wherein X
is H or a one to three peptide group and a peptide bond between
R.sup.A and R.sup.B is labile to aminopeptidase A cleavage; R.sup.3
is selected from the group consisting of Val, Ala, Leu, norLeu,
Ile, Gly, Pro, Aib, Acpc and Tyr; R.sup.4 is selected from the
group consisting of Tyr, Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and
azaTyr; R.sup.5 is selected from the group consisting of Ile, Ala,
Leu, norLeu, Val and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe;
R.sup.7 is Pro or Ala; and R.sup.8 is selected from the group
consisting of Phe, Phe(Br), He and Tyr, excluding sequences
including R.sup.4 as a terminal Tyr group.
3. A method of accelerating the proliferation of mesenchymal
lineage-specific cells comprising contacting the mesenchymal
lineage-specific cells with an amount effective to accelerate
proliferation of mesenchymal lineage-specific cells of at least one
active agent comprising a sequence consisting of at least three
contiguous amino acids of groups R.sup.1-R.sup.8 in the sequence of
general formula I
R.sup.1--R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R-
.sup.7-R.sup.8 in which R.sup.1 and R.sup.2 together form a group
of formula X--R.sup.A--R.sup.B--, wherein X is H or a one to three
peptide group and a peptide bond between R.sup.A and R.sup.B is
labile to aminopeptidase A cleavage; R.sup.3 is selected from the
group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc
and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr, excluding sequences including R.sup.4 as a
terminal Tyr group.
4. A method of accelerating the proliferation of hematopoietic
lineage-specific cells comprising contacting the hematopoietic
lineage-specific cells with an amount effective to accelerate
proliferation of hematopoietic lineage-specific cells of at least
one active agent comprising a sequence consisting of at least three
contiguous ammo acids of groups R.sup.1-R.sup.8 in the sequence of
general formula I
R.sup.1--R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R-
.sup.7-R.sup.8 in which R.sup.1 and R.sup.2 together form a group
of formula X--R.sup.A--R.sup.B--, wherein X is H or a one to three
peptide group and a peptide bond between R.sup.A and R.sup.B is
labile to aminopeptidase A cleavage; R.sup.3 is selected from the
group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc
and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr, excluding sequences including R.sup.4 as a
terminal Tyr group.
5. A method of increasing the differentiation of hematopoietic stem
or lineage-specific cells comprising contacting the hematopoietic
stem or lineage-specific cells with an amount effective to increase
differentiation of the hematopoietic stem or lineage-specific cells
of at least one active agent comprising a sequence consisting of at
least three contiguous amino acids of groups R.sup.1-R.sup.8 in the
sequence of general formula I
R.sup.1--R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R-
.sup.7-R.sup.8 in which R.sup.1 and R.sup.2 together form a group
of formula X--R.sup.A--R.sup.B--, wherein X is H or a one to three
peptide group and a peptide bond between R.sup.A and R.sup.B is
labile to aminopeptidase A cleavage; R.sup.3 is selected from the
group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc
and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr, excluding sequences including R.sup.4 as a
terminal Tyr group.
6. The method of claim 5, wherein the hematopoietic stem or
lineage-specific cells are selected from the group consisting of
macrophages and monocytes.
7. The method of claim 1, 2, 3, 4, 5, or 6 wherein the active agent
is selected from the group consisting of AII, AIII, AII(2-8), SEQ
ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID
NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID
NO:12, SEQ ID NO:13, and SEQ ID NO:31.
8. The method of claims 1, 2, 3, 4, 5, or 6 wherein the
concentration of active agent is between about 0.1 ng/kg and about
1.0 mg/kg.
9. An improved cell culture medium for growth of mesenchymal stem
cells, wherein the improvement comprises addition to the cell
culture medium of an amount effective to accelerate proliferation
of mesenchymal stem cells of at least one active agent comprising a
sequence, consisting of at least three contiguous amino acids of
groups R.sup.1-R.sup.8 in the sequence of general formula I
R.sup.1--R.sup.2--R.sup.3--R.sup.4--R.sup.5-
--R.sup.6--R.sup.7-R.sup.8 in which R.sup.1 and R.sup.2 together
form a group of formula X--R.sup.A--R.sup.B--, wherein X is H or a
one to three peptide group and a peptide bond between R.sup.A and
R.sup.B is labile to aminopeptidase A cleavage; R.sup.3 is selected
from the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro,
Aib, Acpc and Tyr; R.sup.4 is selected from the group consisting of
Tyr, Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr, excluding sequences including R.sup.4 as a
terminal Tyr group.
10. An improved cell culture medium for growth of hematopoietic
lineage-specific cells, wherein the improvement comprises addition
to the cell culture medium of an amount effective to accelerate
proliferation of hematopoietic lineage-specific cells of at least
one active agent comprising a sequence consisting of at least three
contiguous amino acids of groups R.sup.1-R.sup.8 in the sequence of
general formula I
R.sup.1--R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7-R.sup.8
in which R.sup.1 and R.sup.2 together form a group of formula
X--R.sup.A--R.sup.B--, wherein X is H or a one to three peptide
group and a peptide bond between R.sup.A and R.sup.B is labile to
aminopeptidase A cleavage; R.sup.3 is selected from the group
consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and.
Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr, excluding sequences including R.sup.4 as a
terminal Tyr group.
11. An improved cell culture medium for growth of mesenchymal
lineage-specific cells, wherein the improvement comprises addition
to the cell culture medium of an amount effective to accelerate
proliferation of mesenchymal lineage-specific cells of at least one
active agent comprising a sequence consisting of at least three
contiguous amino acids of groups R.sup.1-R.sup.8 in the sequence of
general formula I
R.sup.1--R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7-R.sup.8
in which R.sup.1 and R.sup.2 together form a group of formula
X--R.sup.A--R.sup.B--, wherein X is H or a one to three peptide
group and a peptide bond between R.sup.A and R.sup.B is labile to
aminopeptidase A cleavage; R.sup.3 is selected from the group
consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and
Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr, excluding sequences including R.sup.4 as a
terminal Tyr group.
12. An improved cell culture medium for growth of hematopoietic
lineage-specific cells, wherein the improvement comprises addition
to the cell culture medium of an amount effective to accelerate
proliferation of hematopoietic lineage-specific cells of at least
one active agent comprising a sequence consisting of at least three
contiguous amino acids of groups R.sup.1-R.sup.8 in the sequence of
general formula I
R.sup.1--R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7-R.sup.8
in which R.sup.1 and R.sup.2 together form a group of formula
X--R.sup.A--R.sup.B--, wherein X is H or a one to three peptide
group and a peptide bond between R.sup.A and R.sup.B is labile to
aminopeptidase A cleavage; R.sup.3 is selected from the group
consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and
Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr, excluding sequences including R.sup.4 as a
terminal Tyr group.
13. An improved cell culture medium for differentiation of
hematopoietic stem or lineage-specific cells, wherein the
improvement comprises addition to the cell culture medium an amount
effective to increase differentiation of the hematopoietic stem or
lineage-specific cells of at least one active agent comprising a
sequence consisting of at least three contiguous amino acids of
groups R.sup.1-R.sup.8 in the sequence of general formula I
R.sup.1--R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R-
.sup.7-R.sup.8 in which R.sup.1 and R.sup.2 together form a group
of formula X--R.sup.A--R.sup.B--, wherein X is H or a one to three
peptide group and a peptide bond between R.sup.A and R.sup.B is
labile to aminopeptidase A cleavage; R.sup.3 is selected from the
group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc
and Tyr, R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr, excluding sequences including R.sup.4 as a
terminal Tyr group.
14. The method of claim 13, wherein the hematopoietic stem or
lineage-specific cells are selected from the group consisting
essentially of macrophages and monocytes.
15. The improved cell culture medium of claim 9, 10, 11, 12, 13, or
14 wherein the active agent is selected from the group consisting
of AII, AIII, AII(2-8), SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ
ID NO:5,, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ
ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID
NO:31.
16. The improved cell culture medium of claim 9, 10, 11, 12, 13, or
14 wherein the concentration of active agent is between about 0.1
ng/kg and about 1.0 mg/kg.
17. A kit for the propagation of mesenchymal stem cells,
comprising: (a) an amount effective to accelerate proliferation of
mesenchymal stem cells of at least one active agent comprising a
sequence consisting of at least three contiguous amino acids of
groups R.sup.1-R.sup.8 in the sequence of general formula I
R.sup.1--R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R-
.sup.7-R.sup.8 in which R.sup.1 and R.sup.2 together form a group
of formula X--R.sup.A--R.sup.B--, wherein X is H or a one to three
peptide group and a peptide bond between R.sup.A and R.sup.B is
labile to aminopeptidase A cleavage; R.sup.3 is selected from the
group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc
and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala, and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr, excluding sequences including R.sup.4 as a
terminal Tyr group; and (b) instructions for using the amount
effective of active agent as a cell culture medium supplement.
18. The kit of claim 17, further comprising mesenchymal stem cell
growth medium.
19. A kit for the propagation of hematopoietic lineage-specific
cells, comprising: (a) an amount effective to accelerate
proliferation of hematopoietic lineage-specific cells of at least
one active agent comprising a sequence consisting of at least three
contiguous amino acids of groups R.sup.1-R.sup.8 in the sequence of
general formula I
R.sup.1--R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7-R.sup.8
in which R.sup.1 and R.sup.2 together form a group of formula
X--R.sup.A--R.sup.B--, wherein X is H or a one to three peptide
group and a peptide bond between R.sup.A and R.sup.B is labile to
aminopeptidase A cleavage; R.sup.3 is selected from the group
consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and
Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr, excluding sequences including R.sup.4 as a
terminal Tyr group; and (b) instructions for using the amount
effective of active agent as a cell culture medium supplement.
20. The kit of claim 19, further comprising hematopoietic
lineage-specific cell growth medium.
21. A kit for the propagation of mesenchymal lineage-specific
cells, comprising: (a) an amount effective to accelerate
proliferation of mesenchymal lineage-specific cells of at least one
active agent comprising a sequence consisting of at least three
contiguous amino acids of groups R.sup.1-R.sup.8 in the sequence of
general formula I
R.sup.1--R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7-R.sup.8
in which R.sup.1 and R.sup.2 together form a group of formula
X--R.sup.A--R.sup.B--, wherein X is H or a one to three peptide
group and a peptide bond between R.sup.A and R.sup.B is labile to
aminopeptidase A cleavage; R.sup.3 is selected from the group
consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and
Tyr, R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr, excluding sequences including R.sup.4 as a
terminal Tyr group; and (b) instructions for using the amount
effective of active agent as a cell culture medium supplement.
22. The kit of claim 21, further comprising mesenchymal
lineage-specific cell growth medium.
23. A kit for the propagation of hematopoietic lineage-specific
cells, comprising: (a) an amount effective to accelerate
proliferation of hematopoietic lineage-specific cells of at least
one active agent comprising a sequence consisting of at least three
contiguous amino acids of groups R.sup.1-R.sup.8 in the sequence of
general formula I
R.sup.1--R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7-R.sup.8
in which R.sup.1 and R.sup.2 together form a group of formula
X--R.sup.A--R.sup.B--, wherein X is H or a one to three peptide
group and a peptide bond between R.sup.A and R.sup.B is labile to
aminopeptidase A cleavage; f R.sup.3 is selected from the group
consisting of Val, Ala, Leu, norLeu, le, Gly, Pro, Aib, Acpc and
Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr, excluding sequences including R.sup.4 as a
terminal Tyr group; and (b) instructions for using the amount
effective of active agent as a cell culture medium supplement.
24. The kit of claim 23, further comprising hematopoietic
lineage-specific cell growth medium.
25. A kit for the differentiation of hematopoietic stem or
lineage-specific cells, comprising: (a) an amount effective to
accelerate differentiation of hematopoietic stem or
lineage-specific cells of at least one active agent comprising a
sequence consisting of at least three contiguous amino acids of
groups R.sup.1-R.sup.8 in the sequence of general formula I
R.sup.1--R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R-
.sup.7-R.sup.8 in which R.sup.1 and R.sup.2 together form a group
of formula X--R.sup.A--R.sup.B--, wherein X is H or a one to three
peptide group and a peptide bond between R.sup.A and R.sup.B is
labile to aminopeptidase A cleavage; R.sup.3 is selected from the
group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc
and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr, excluding sequences including R.sup.4 as a
terminal Tyr group. (b) instructions for using the amount effective
of active agent as a cell culture medium supplement.
26. The kit of claim 25, wherein the hematopoietic stem or
lineage-specific cells are selected from the group consisting of
macrophages and monocytes.
27. The kit of claim 25 or 26, further comprising hematopoietic
lineage-specific cell growth medium.
28. The kit of claim 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27
further comprising a sterile container.
29. The kit of claim 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27
wherein the active agent is selected from the group consisting of
AII, AIII, AII(2-8), SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID
NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID
NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, and SEQ ID
NO:31.
30. The kit of claim 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or 27
wherein the concentration of active agent is between about 0.1
ng/kg and about 1.0 mg/kg.
31. A method of accelerating the proliferation of mesenchymal stem
cells comprising contacting the mesenchymal stem cells with an
amount effective to accelerate proliferation of mesenchymal stem
cells of at least one active agent comprising a sequence consisting
of at least three contiguous amino acids of groups R.sup.2-R.sup.8
in the sequence of general formula II
R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7--- R.sup.8 in
which R.sup.2 is selected from the group consisting of H, Arg, Lys,
Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys; R.sup.3 is selected from
the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib,
Acpc and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr.
32. A method of accelerating the proliferation of hematopoietic
lineage-specific cells comprising contacting the hematopoietic
lineage-specific cells with an amount effective to accelerate
proliferation of hematopoietic lineage-specific cells of at least
one active agent comprising a sequence consisting of at least three
contiguous amino acids of groups R.sup.2-R.sup.8 in the sequence of
general formula II
R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7--- R.sup.8 in
which R.sup.2 is selected from the group consisting of H, Arg, Lys,
Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys; R.sup.3 is selected from
the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib,
Acpc and Tyr, R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), He and Tyr.
33. A method of accelerating the proliferation of mesenchymal
lineage-specific cells comprising contacting the mesenchymal
lineage-specific cells with an amount effective to accelerate
proliferation of mesenchymal lineage-specific cells of at least one
active agent comprising a sequence consisting of at least three
contiguous amino acids of groups R.sup.2-R.sup.8 in the sequence of
general formula II
R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7--- R.sup.8 in
which R.sup.2 is selected from the group consisting of H, Arg, Lys,
Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys; R.sup.3 is selected from
the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib,
Acpc and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr.
34. A method of accelerating the proliferation of hematopoietic
lineage-specific cells comprising contacting the hematopoietic
lineage-specific cells with an amount effective to accelerate
proliferation of hematopoietic lineage-specific cells of at least
one active agent comprising a sequence consisting of at least three
contiguous amino acids of groups R.sup.2-R.sup.8 in the sequence of
general formula II
R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7--- R.sup.8 in
which R.sup.2 is selected from the group consisting of H, Arg, Lys,
Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys; R.sup.3 is selected from
the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib,
Acpc and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr.
35. A method of increasing the differentiation of hematopoietic
stem or lineage-specific cells comprising contacting the
hematopoietic stem or lineage-specific cells with an amount
effective to increase differentiation of the hematopoietic stem or
lineage-specific cells of at least one active agent comprising a
sequence consisting of at least three contiguous amino acids of
groups R.sup.2-R.sup.8 in the sequence of general formula II
R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7--- R.sup.8 in
which R.sup.2 is selected from the group consisting of H, Arg, Lys,
Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys; R.sup.3 is selected from
the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib,
Acpc and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Try.
36. The method of claim 35, wherein the hematopoietic stem or
lineage-specific cells are selected from the group consisting of
macrophages and monocytes.
37. The method of claim 31, 32, 33, 34, 35, or 36 wherein the
active agent is selected from the group consisting of SEQ ID NO:2,
SEQ ID NO:17, and SEQ ID NO:18.
38. The method of claims 31, 32, 33, 34, 35, or 36 wherein the
concentration of active agent is between about 0.1 ng/kg and about
1.0 mg/kg.
39. An improved cell culture medium for growth of mesenchymal stem
cells, wherein the improvement comprises addition to the cell
culture medium of an amount effective to accelerate proliferation
of mesenchymal stem cells of at least one active agent comprising a
sequence consisting of at least three contiguous amino acids of
groups R.sup.2-R.sup.8 in the sequence of general formula II
R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7--- R.sup.8 in
which R.sup.2 is selected from the group consisting of H, Arg, Lys,
Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys; R.sup.3 is selected from
the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib,
Acpc and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr.
40. An improved cell culture medium for growth of hematopoietic
lineage-specific cells, wherein the improvement comprises addition
to the cell culture medium of an amount effective to accelerate
proliferation of hematopoietic lineage-specific cells of at least
one active agent comprising a sequence consisting of at least three
contiguous amino acids of groups R.sup.2-R.sup.8 in the sequence of
general formula II
R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7--R.sup.8 in
which R.sup.2 is selected from the group consisting of H, Arg, Lys,
Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys; R.sup.3 is selected from
the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib,
Acpc and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr.
41. An improved cell culture medium for grown of mesenchymal
lineage-specific cells, wherein the improvement comprises addition
to the cell culture medium of an amount effective to accelerate
proliferation of mesenchymal lineage-specific cells of at least one
active agent comprising a sequence consisting of at least three
contiguous amino acids of groups R.sup.2-R.sup.8 in the sequence of
general formula II
R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7--R.sup.8 in
which R.sup.2 is selected from the group consisting of H, Arg, Lys,
Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys; R.sup.3 is selected from
the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib,
Acpc and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr.
42. An improved cell culture medium for growth of hematopoietic
lineage-specific cells, wherein the improvement comprises addition
to the cell culture medium of an amount effective to accelerate
proliferation of hematopoietic lineage-specific cells of at least
one active agent comprising a sequence consisting of at least three
contiguous amino acids of groups R.sup.2-R.sup.8 in the sequence of
general formula II
R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7--R.sup.8 in
which R.sup.2 is selected from the group consisting of H, Arg, Lys,
Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys; R.sup.3 is selected from
the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib,
Acpc and Tyr, R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr.
43. An improved cell culture medium for differentiation of
hematopoietic stem or lineage-specific cells, wherein the
improvement comprises addition to the cell culture medium an amount
effective to increase differentiation of the hematopoietic stem or
lineage-specific cells of at least one active agent comprising a
sequence consisting of at least three contiguous amino acids of
groups R.sup.2-R.sup.8 in the sequence of general formula II
R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7--- R.sup.8 in
which R.sup.2 is selected from the group consisting of H, Arg, Lys,
Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys; R.sup.3 is selected from
the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib,
Acpc and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr.
44. The method of claim 43, wherein the hematopoietic stem or
lineage-specific cells are selected from the group consisting of
macrophages and monocytes.
45. The improved cell culture medium of claim 39, 40 41, 42, 43, or
44 wherein the active agent is selected from the group consisting
SEQ ID NO:2, SEQ ID NO:17, and SEQ ID NO:18.
46. The improved cell culture medium of claim 39, 40, 41, 42, 43,
or 44 wherein the concentration of active agent is between about
0.1 ng/kg and about 1.0 mg/kg.
47. A kit for the propagation of mesenchymal stem cells,
comprising: (a) an amount effective to accelerate proliferation of
mesenchymal stem cells of at least one active agent comprising a
sequence consisting of at least three contiguous amino acids of
groups R.sup.2-R.sup.8 in the sequence of general formula II
R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7--- R.sup.8 in
which R.sup.2 is selected from the group consisting of H, Arg, Lys,
Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys; R.sup.3 is selected from
the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib,
Acpc and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr; and (b) instructions for using the amount
effective of active agent as a cell culture medium supplement.
48. The kit of claim 47, further comprising mesenchymal stem cell
growth medium.
49. A kit for the propagation of hematopoietic lineage-specific
cells, comprising: (a) an amount effective to accelerate
proliferation of hematopoietic lineage-specific cells of at least
one active agent comprising a sequence consisting of at least three
contiguous amino acids of groups R.sup.2-R.sup.8 in the sequence of
general formula II
R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7--R.sup.8 in
which R.sup.2 is selected from the group consisting of H, Arg, Lys,
Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys; R.sup.3 is selected from
the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib,
Acpc and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr; and ;(b) instructions for using the amount
effective of active agent as a cell culture medium supplement.
50. The kit of claim 49, further comprising hematopoietic
lineage-specific cell growth medium.
51. A kit for the propagation of mesenchymal lineage-specific
cells, comprising: (a) an amount effective to accelerate
proliferation of mesenchymal lineage-specific cells of at least one
active agent comprising a sequence consisting of at least three
contiguous amino acids of groups R.sup.2-R.sup.8 in the sequence of
general formula II
R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7--R.sup.8 in
which R.sup.2 is selected from the group consisting of H, Arg, Lys,
Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys; R.sup.3 is selected from
the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib,
Acpc and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr, and (b) instructions for using the amount
effective of active agent as a cell culture medium supplement.
52. The kit of claim 51, further comprising mesenchymal
lineage-specific cell growth medium.
53. A kit for the propagation of hematopoietic lineage-specific
cells, comprising: (a) an amount effective to accelerate
proliferation of hematopoietic lineage-specific cells of at least
one active agent comprising a sequence consisting of at least three
contiguous amino acids of groups R.sup.2-R.sup.8 in the sequence of
general formula II
R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7--R.sup.8 in
which R.sup.2 is selected from the group consisting of H, Arg, Lys,
Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys; R.sup.3 is selected from
the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib,
Acpc and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr; and (b) instructions for using the amount
effective of active agent as a cell culture medium supplement.
54. The kit of claim 53, further comprising hematopoietic
lineage-specific cell growth medium.
55. A kit for the differentiation of hematopoietic stem or
lineage-specific cells, comprising: (a) an amount effective to
accelerate differentiation of hematopoietic stem or
lineage-specific cells of at least one active agent comprising a
sequence consisting of at least three contiguous amino acids of
groups R.sup.2-R.sup.8 in the sequence of general formula II
R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7--- R.sup.8 in
which R.sup.2 is selected from the group consisting of H, Arg, Lys,
Ala, Orn, Se r(Ac), Sar, D-Arg and D-Lys; R.sup.3 is selected from
the group consisting of Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib,
Acpc and Tyr; R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr; R.sup.5 is
selected from the group consisting of Ile, Ala, Leu, norLeu, Val
and Gly; R.sup.6 is His, Arg or 6-NH.sub.2-Phe; R.sup.7 is Pro or
Ala; and R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr; and (b) instructions for using the amount
effective of active agent as a cell culture medium supplement.
56. The kit of claim 55, wherein the hematopoietic stem or
lineage-specific cells are selected from the group consisting of
macrophages and monocytes.
57. The kit of claim 55 or 56, further comprising hematopoietic
lineage-specific cell growth medium.
58. The kit of claim 47, 48, 49, 50, 51, 52, 53, 54, 55, 56 or 57
further comprising a sterile container.
59. The kit of claim 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, or 57
wherein the active agent is selected from the group consisting of
SEQ ID NO:2, SEQ ID NO:17, and SEQ ID NO:18.
60. The kit of claim 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, or 57
wherein the concentration of active agent is between about 0.1
ng/kg and about 1.0 mg/kg.
Description
CROSS REFERENCE
[0001] This application is a Continuation-In-Part of U.S.
Provisional Application No. 60/036,507, filed Jan. 28, 1997, No.
60/046,859, filed May 8, 1997; No. 60/063,684 filed Oct. 28, 1997;
No. 60/063,910 filed Oct. 31, 1997; No. 60/065,612 filed Nov. 18,
1997; and No. 60/066,593 filed Nov. 26, 1997.
FIELD OF THE INVENTION
[0002] This present invention relates to methods and kits for use
in accelerating the proliferation and differentiation of
hematopoietic and mesenchymal cells.
BACKGROUND OF THE INVENTION
[0003] Bone marrow contains pluripotent stem cells that are capable
of reconstituting either the hematopoietic system or a wide range
of mesenchymal tissues. The mechanisms by which hematopoietic and
mesenchymal stem cells produce a range of lineage-specific cell
types are quite dissimilar.
[0004] a. The Hematopoietic System
[0005] The hematopoietic system is composed of a multitude of cell
generations ranging from the terminally differentiated to very
primitive hematopoietic lineage-specific cells, including a
multipotent, self-renewing hematopoietic stem cell with long-term
repopulating capability (HPC). (Traycoff, et al., Experimental
Hematology 24:299-306, 1996). HPC are pluripotent lineage-specific
cells that possess the ability to terminally differentiate into
hematopoietic lineage-specific cells (HLSC). Hematopoiesis is an
ongoing process, and therefore HPC must provide a continuous source
of HLSC, which in turn can differentiate into red cells, platelets,
monocytes, granulocytes and lymphocytes. (Prockop, Science
276:71-74, 1997). HPC proliferate either by "self-renewal", to
produce HPC-type progeny cells, or with accompanying
differentiation, to produce HLSC. (Traycoff, et al., supra).
[0006] HPC transplantation therapy has been successful for a
variety of malignant and inherited diseases and also provides
myelopoietic support for patients undergoing high-dose chemotherapy
or radiotherapy. (Emerson, Blood 87:3082-3088, 1996). However, stem
cell transplantation has been limited by several features. First,
acquiring a sufficient quantity of stem cells to achieve benefit
after transfusion requires either extensive, operative bone marrow
harvests or extensive pheresis procedures. (Emerson, supra). Next,
even under these circumstances, only a limited number of useful
cells is obtained. Finally, mature: blood cell regeneration after
transfusion is slow, so that little direct therapeutic benefit is
seen for periods of 1 to 3 weeks. (Emerson, supra).
[0007] The development of in vitro culture techniques for
hematopoietic cells combined with technologies for isolating
relatively pure populations of HPC and HLSC has made possible their
ex vivo expansion. (Alcorn and Holyoake, Blood Reviews 10:167-176,
1996, which is incorporated by reference herein). Successful ex
vivo expansion of HPC, both by self-renewal and proliferation with
differentiation, promises many clinical benefits, such as reduction
of the number and duration of leucapheresis procedures required for
autologous transplantation, thus reducing the risk of disease
contamination in the apheresis products. (Alcorn and Holyoake,
supra). Furthermore, ex vivo expansion may render inadequate HPC
populations in peripheral blood and umbilical cord blood sufficient
for autologous transplantation and adult allogeneic transplantation
respectively. Finally, ex vivo expansion of HPC will greatly
increase their utility as gene therapy vehicles. (Alcorn and
Holyoake, supra). Similarly, ex vivo expansion of HLSC promises
substantial clinical benefits, such as re-infusion of expanded
populations of myeloid precursor cells to reduce the period of
obligate neutropenia following autologous transplantation, the
generation of natural killer cells for use in adoptive
immunotherapy protocols, generation of megakaryocyte precursors to
alleviate post-transplant-associated thrombocytopenia and more
efficient generation of delivery systems for gene therapy. (Alcorn
and Holyoake, supra).
[0008] Human bone marrow, umbilical cord blood, and peripheral
blood lineage-specific cells mobilized by chemotherapy and/or
cytokine treatment have been shown to be effective sources of HPC
for transplantation following the administration of high-dose
therapy to treat malignancy. (Holyoake, et al., Blood 87:4589-4595,
1996). Whatever the source of hematopoietic cells, most studies
have used cultured cell populations selected on the basis of
HPC-specific surface antigens, such as CD34. These cells can be
readily obtained by a number of techniques. (Alcorn and Holyoake,
supra). The results of several clinical trials using ex vivo
expanded hematopoietic cells suggests that a fairly small number of
HPC cultured ex vivo under appropriate conditions can initiate
hematologic reconstitution. (Emerson, supra).
[0009] Survival and proliferation of HPC in ex vivo culture
requires a combination of synergizing growth factors; the choice of
cytokine/growth factor combination and culture system used will
largely determine the fate of cells used to initiate the culture.
(Alcorn and Holyoake, supra). In vivo, blood cell production is
thought to be regulated locally by interactions of hematopoietic
stem cells with a variety of cell-bound and secreted factors
produced by adjacent bone marrow stromal cells. (Alcorn and
Holyoake, supra). The addition of growth factors and cytokines to
the culture medium is intended to compensate for the absence of
stroma-associated activities. Growth factors and cytokines that
have been shown to increase production of HPC (in various
combinations) include granulocyte colony-stimulating factor
(G-CSF), granulocyte/macrophage colony stimulating factor (GM-CSF),
stem cell factor (SCF), macrophage colony-stimulating factor
(M-CSF), and interleukins 1, 3, 6, and 11 (Reviewed in Takaku, J.
Cancer Res. Clin. Oncol. 121:701-709, 1995; Holyoake, et al.,
supra). Conversely, inclusion of macrophage inhibitory
protein-1.alpha. (MIP-1.alpha.), tumor necrosis factor .alpha.
(TNF-.alpha.) or transforming growth factor .beta. (TGF.beta.) in
most expansion cultures reported to date results in decreased HPC
and HLSC yields. (Emerson, supra).
[0010] A great deal of effort has gone into defining the optimal
conditions for ex vivo culture of hematopoietic cells. Improved
methods that increase of ex vivo proliferation rate of HPC will
greatly increase the clinical benefits of HPC transplantation. This
is true both for increased "self-renewal", which will provide a
larger supply of HPC capable of reconstituting the entire
hematopoietic system, and for proliferation with differentiation,
which will provide a larger supply of lineage-specific cells.
Similarly, methods that increase in vivo proliferation of HPC will
enhance the utility of HPC transplantation therapy by rapidly
increasing local concentrations of HPC (and HLSC) in the bone
marrow. Furthermore, methods that result in the differentiation of
HPC and HLSC are useful in providing populations of specific cell
types for use in cell therapy.
[0011] Transfection of mammalian HPC has been accomplished.
(Larochelle, et al., Nature Medicine 2:1329-1337, 1996). Thus,
methods that increase the proliferation of HBC and HLSC are also
useful in rapidly providing a large population of transfected cells
for use in gene therapy.
[0012] b. Mesenchymal Stem Cells
[0013] Mesenchymal stem cells (MSC) are pluripotent progenitor
cells that possess the ability to differentiate into a variety of
mesenchymal tissue, including bone, cartilage, tendon, muscle,
marrow stroma, fat and dermis as demonstrated in a number of
organisms, including humans (Bruder, et al., J. Cellul. Biochem.
56:283-294 (1994). The formation of mesenchymal tissues is known as
the mesengenic process, which continues throughout life, but
proceeds much more slowly in the adult than in the embryo (Caplan,
Clinics in Plastic Surgery 21:429-435 (1994). The mesengenic
process in the adult is a repair process but involves the same
cellular events that occur during embryonic development (Reviewed
in Caplan, 1994, supra). During repair processes, chemoattraction
brings MSC to the site of repair where they proliferate into a mass
of cells that spans the break. These cells then undergo commitment
and enter into a specific lineage pathway (differentiation), where
they remain capable of proliferating. Eventually, the cells in the
different pathways terminally differentiate (and are no longer able
to proliferate) and combine to form the appropriate skeletal
tissue, in a process controlled by the local concentration of
tissue-specific cytokines and growth factors (Caplan, 1994,
supra).
[0014] Recently, it has been hypothesized that the limiting factor
for MSC-based repair processes is the lack of adequate numbers of
responsive MSC at the repair site (Caplan, 1994, supra). Thus, it
has been suggested that by supplying a sufficient number of MSC to
a specific tissue site the repair process can be controlled, since
the repair site will supply the appropriate exposure to
lineage-specific growth factors and differentiation molecules
(Caplan, 1994, supra). Towards this end, several animal studies
have demonstrated the feasibility of using autologous MSC for
repair of various defects associated with mesenchymal tissue. (For
review, see Caplan, et al., in The Anterior Cruciate Ligament:
Current and Future Concepts, ed. D. W. Jackson, Raven Press, Ltd.
NY pp.405-417 (1993). Recent work has demonstrated the feasibility
of collection, ex vivo expansion in culture, and intravenous
infusion of MSC in humans (Lazarus, et al., Bone Marrow
Transplantation 16:557-564 (1995); Caplan and Haynesworth, U.S.
Pat. No. 5,486,359, hereby incorporated by reference in its
entirety). Further, MSC of animal origin have been transfected with
retroviruses and have achieved high level gene expression both in
vitro and in vivo (Allay, et al., Blood 82:477A (1993). Thus, the
manipulation of MSC via such techniques seems a promising tool for
reconstructive therapies and may be useful for gene therapy.
[0015] MSC therapy can serve as a means to deliver high densities
of repair-competent cells to a defect site when adequate numbers of
MSC and MSC lineage-specific cells are not present in vivo,
especially in older and/or diseased patients. In order to
efficiently deliver high densities of MSC to a defect site, methods
for rapidly producing large numbers of MSC are necessary. MSC have
been exposed to a number of growth factors in vitro, but only
platelet-derived growth factor (PDGF) showed mitotic activity
(Caplan et al., 1994, supra). Methods that increase the ex vivo
proliferation rate of MSC will greatly increase the utility of MSC
therapy. Similarly, methods that increase in vivo proliferation
rate of MSC will enhance the utility of MSC therapy by rapidly
increasing local concentrations of MSC at the repair site.
[0016] Furthermore, methods that enhance the proliferation rate of
lineage-specific descendants of MSC, including but not limited to
bone marrow stromal cells, osteoclasts, chondrocytes, and
adipocytes, will enhance the therapeutic utility of MSC therapy by
increasing the concentration of lineage-specific cell types at
appropriate repair sites.
SUMMARY OF THE INVENTION
[0017] In one aspect, the present invention provides methods that
promote hematopoietic stem and lineage-specific cell proliferation
and differentiation, and mesenchymal stem and lineage-specific cell
proliferation by contacting the cells with angiotensinogen,
angiotensin I (AI), AI analogues, AI fragments and analogues
thereof, angiotensin II (AII), AII analogues, AII fragments or
analogues thereof or AII AT.sub.2 type 2 receptor agonists, either
alone or in combination with other growth factors and
cytokines.
[0018] In another aspect of the present invention, an improved cell
culture medium is provided for the proliferation and
differentiation of hematopoietic stem and lineage-specific cells,
and for the proliferation of mesenchymal stem and lineage-specific
cells, wherein the improvement comprises addition to the cell
culture medium of an effective amount of angiotensinogen, AI, AI
analogues, AI fragments and analogues thereof, AII, AII analogues,
AII fragments or analogues thereof or AII AT.sub.2 type 2 receptor
agonists.
[0019] In a further aspect, the present invention provides kits for
the propagation of hematopoietic and mesenchymal stem and
lineage-specific cells, wherein the kits comprise cell an effective
amount of angiotensinogen, AI, AI analogues, AI fragments and
analogues thereof, AII, AII analogues, AII fragments or analogues
thereof or AII AT.sub.2 type 2 receptor agonists, and instructions
for using the amount effective of active agent as a cell culture
medium supplement. In a preferred embodiment, the kit further
comprises a cell culture media. In another preferred embodiment,
the kit further comprises a sterile container for cell
culturing.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0020] As defined herein, the term "HPC" refers to any
hematopoietic pluripotent progenitor cells capable of giving rise
to a wide variety of differentiated hematopoietic cell types. Cell
types from this definition include, but are not limited to
CD34.sup.+ bone marrow mononuclear cells (BMMC) (Berardi, et al.,
Blood 86:2123-2129, 1995), PBSC (Fritsch, et al., Bone Marrow
transplantation 17:169-178, 1996), cobblestone area forming cells
(CAFC) (Lemieux, et al., Blood 86:1339-1347, 1995) and 5-FU BM
cells (Alcorn and Holyoake, Blood Reviews 10:167-176, 1996). As
defined herein, the term "HLSC" refers to hematopoietic
lineage-specific cells, and includes the progeny of HPC that are
committed to a cell-specific differentiation pathway, as well as
fully differentiated hematopoietic cells. As defined herein,
mesenchymal stem cells (MSC) are pluripotent progenitor cells that
possess the ability to differentiate into a variety of mesenchymal
tissue, including bone, cartilage, tendon, muscle, marrow stroma,
fat and dermis, and include, but are not limited to, cells such as
those described in Caplan and Haynesworth, U.S. Pat. No. 5,486,359.
As defined herein, "proliferation" encompasses both cell self
renewal and cellular proliferation with accompanying
differentiation. As defined herein "differentiation" includes both
entry into a specific lineage pathway and functional activation of
differentiated cells.
[0021] U.S. Pat. No. 5,015,629 to DiZerega (the entire disclosure
of which is hereby incorporated by reference) describes a method
for increasing the rate of healing of wound tissue, comprising the
application to such tissue of angiotensin II (AII) in an amount
which is sufficient for said increase. The application of AII to
wound tissue significantly increases the rate of wound healing,
leading to a more rapid re-epithelialization and tissue repair. The
term AII refers to an octapeptide present in humans and other
species having the sequence Asp-Arg-Val-Tyr-Ile-His-Pro-- Phe [SEQ
ID NO:1]. The biological formation of angiotensin is initiated by
the action of renin on the plasma substrate angiotensinogen
(Clouston et al., Genomics 2:240-248 (1988); Kageyama et al,
Biochemistry 23:3603-3609; Ohkubo et al., Proc. Natl. Acad. Sci.
80:2196-2200 (1983); each reference hereby incorporated in its
entirety). The substance so formed is a decapeptide called
angiotensin I (AI) which is converted to AII by the converting
enzyme angiotensinase which removes the C-terminal His-Leu residues
from AI [SEQ ID NO:38]. AII is a known pressor agent and is
commercially available.
[0022] Studies have shown that AI increases mitogenesis and
chemotaxis in cultured cells that are involved in wound repair, and
also increases their release of growth factors and extracellular
matrices (diZerega, U.S. Pat. No. 5,015,629; Dzau et. al., J. Mol.
Cell. Cardiol. 21:S7 (Supp III) 1989; Berk et. al., Hypertension
13:305-14 (1989); Kawahara, et al., BBRC 150:52-9 (1988); Naftilan,
et al., J. Clin. Invest. 83:1419-23 (1989); Taubman et al., J.
Biol. Chem. 264:526-530 (1989); Nakahara, et al., BBRC 184:811-8
(1992); Stouffer and Owens, Circ. Res. 70:820 (1992); Wolf, et al.,
Am. J. Pathol. 140:95-107 (1992); Bell and Madri, Am. J. Pathol.
137;7-12 (1990). In addition, AII was shown to be angiogenic in
rabbit corneal eye and chick chorioallantoic membrane models
(Fernandez, et al., J. Lab. Clin. Med. 105:141 (1985); LeNoble, et
al., Eur. J. Pharmacol. 195:305-6 (1991). Therefore, AII may
accelerate wound repair through increased neovascularization,
growth factor release, reepithelialization and/or production of
extracellular matrix. However, it is not known in the literature as
to whether angiotensinogen, AI, AI analogues, AI fragments and
analogues thereof, AII, AII analogues and fragments thereof, or AII
receptor agonists would be useful in accelerating the proliferation
and differentiation of hematopoietic and mesenchymal stem and
lineage-specific cells.
[0023] A peptide agonist selective for the AT2 receptor (AII has
100 times higher affinity for AT2 than AT1) has been identified.
This peptide is p-amninophenylalanine6-AII
["p-NH.sub.2-Phe)6-AII)"], Asp-Arg-Val-Tyr-Ile-Xaa-Pro-Phe [SEQ ID
NO.36] wherein Xaa is p-NH.sub.2-Phe (Speth and Kim, BBRC
169:997-1006 (1990). This peptide gave binding characteristics
comparable to AT2 antagonists in the experimental models tested
(Catalioto, et al., Eur. J. Pharmacol. 256:93-97 (1994); Bryson, et
al., Eur. J. Pharmacol. 225:119-127 (1992).
[0024] The effects of AII receptor and AII receptor antagonists
have been examined in two experimental models of vascular injury
and repair which suggest that both AII receptor subtypes (AT1 and
AT2) play a role in wound healing (Janiak et al., Hypertension
20:737-45 (1992); Prescott, et al., Am. J. Pathol. 139:1291-1296
(1991); Kauffman, et al., Life Sci. 49:223-228 (1991); Viswanathan,
et al., Peptides 13:783-786 (1992); Kimura, et al., BBRC
187:1083-1090 (1992).
[0025] Many studies have focused upon AII(1-7) (AII residues 1-7)
or other fragments of AII to evaluate their activity. AII(1-7)
elicits some, but not the full range of effects elicited by AII.
Pfeilschifter, et al., Eur. J. Pharmacol. 225:57-62 (1992);
Jaiswal, et al., Hypertension 19(Supp. II):II-49-II-55 (1992);
Edwards and Stack, J. Pharmacol. Exper. Ther. 266:506-510 (1993);
Jaiswal, et al., J. Pharmacol. Exper. Ther. 265:664-673 (1991);
Jaiswal, et al., Hypertension 17:1115-1120 (1-991); Portsi, et a,
Br. J. Pharmacol. 111:652-654 (1994).
[0026] As hereinafter defined, a preferred class of AT2 agonists
for use in accordance with the present invention comprises AII, AII
analogues or active fragments thereof having p-NH-Phe in a position
corresponding to a position 6 of AII. In addition to peptide
agents, various nonpeptidic agents (e.g., peptidomimetics) having
the requisite AT2 agonist activity are further contemplated for use
in accordance with the present invention.
[0027] The active AII analogues, fragments of AII and analogues
thereof of particular interest in accordance with the present
invention comprise a sequence consisting of at least three
contiguous amino acids of groups R.sup.1-R.sup.8 in the sequence of
general
[0028] formula I
R.sup.1--R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7-R.sup.8
[0029] in which R.sup.1 and R.sup.2 together form a group of
formula
X--R.sup.A--R.sup.B--,
[0030] wherein X is H or a one to three peptide group and a peptide
bond between R.sup.A and R.sup.B is labile to aminopeptidase A
cleavage;
[0031] R.sup.3 is selected from the group consisting of Val, Ala,
Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and Tyr;
[0032] R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr;
[0033] R.sup.5 is selected from the group consisting of Ile, Ala,
Leu, norLeu, Val and Gly;
[0034] R.sup.6 is His, Arg or 6-NH.sub.2-Phe;
[0035] R.sup.7 is Pro or Ala and
[0036] R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr, excluding sequences including R.sup.4 as a
terminal Tyr group.
[0037] Compounds falling within the category of AT2 agonists useful
in the practice of the invention include the AII analogues set
forth above subject to the restriction that R.sup.6 is
p-NH.sub.2-Phe.
[0038] In one class of preferred embodiments, R.sup.A is suitably
selected from Asp, Glu, Asn, Acpc (1-aminocyclopentane carboxylic
acid), Ala, Me.sup.2Gly, Pro, Bet, Glu(NH.sub.2), Gly,
Asp(NH.sub.2) and Suc. R.sup.B is suitably selected, from Arg, Lys,
Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys. Particularly preferred
combinations for R.sup.A and R.sup.B are Asp-Arg, Asp-Lys, Glu-Arg
and Glu-Lys.
[0039] Particularly preferred embodiments of this class include the
following: AII, AIII or AII(2-8), Arg-Val-Tyr-Ile-His-Pro-Phe [SEQ
ID NO:2]; AII(3-8), also known as des1-AIII or AIV,
Val-Tyr-Ile-His-Pro-Phe [SEQ ID NO:3]; AII(1-7),
Asp-Arg-Val-Tyr-Ile-His-Pro {SEQ ID NO:4]; AII(2-7).
Arg-Val-Tyr-Ile-His-Pro [SEQ ID NO:5]; AII(3-7),
Val-Tyr-Ile-His-Pro [SEQ ID NO:6]; AII(5-8), Ile-His-Pro-Phe [SEQ
ID NO:7]; AII(1-6), Asp-Arg-Val-Tyr-Ile-His [SEQ ID NO:8];
AII(1-5), Asp-Arg-Val-Tyr-Ile [SEQ ID NO:9]; AII(1-4),
Asp-Arg-Val-Tyr [SEQ ID NO:10]; and AII(1-3), Asp-Arg-Val [SEQ ID
NO:11]. Other preferred embodiments include:
Arg-norLeu-Tyr-Ile-His-Pro-Phe [SEQ ID NO:12] and
Arg-Val-Tyr-norLeu-His-Pro-Phe [SEQ ID NO:13]. Still another
preferred embodiment encompassed within the scope of the invention
is a peptide having the sequence Asp-Arg-Pro-Tyr-Ile-His-Pro-Phe
[SEQ ID NO:31]. AII(6-8), His-Pro-Phe [SEQ ID NO:14] and AII(4-8),
Tyr-Ile-His-Pro-Phe [SEQ ID NO:15] were also tested and found not
to be effective.
[0040] Another class of compounds of particular interest in
accordance with the present invention are those of the general
formula II
R.sup.2--R.sup.3--R.sup.4--R.sup.5--R.sup.6--R.sup.7--R.sup.8
[0041] in which R.sup.2 is selected from the group consisting of H,
Arg, Lys, Ala, Orn, Ser(Ac), Sar, D-Arg and D-Lys;
[0042] R.sup.3 is selected from the group consisting of Val, Ala,
Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and Tyr,
[0043] R.sup.4 is selected from the group consisting of Tyr,
Tyr(PO.sub.3).sub.2, Thr, Ser, homoSer and azaTyr;
[0044] R.sup.5 is selected from the group consisting of Ile, Ala,
Leu, norLeu, Val and Gly;
[0045] R.sup.6 is His, Arg or 6-NH.sub.2-Phe;
[0046] R.sup.7 is Pro or Ala; and
[0047] R.sup.8 is selected from the group consisting of Phe,
Phe(Br), Ile and Tyr.
[0048] A particularly preferred subclass of the compounds of
general formula II has the formula
R.sup.2--R.sup.3-Tyr-R.sup.5-His-Pro-Phe [SEQ ID NO:16]
[0049] wherein R.sup.2, R.sup.3 and R.sup.5 are as previously
defined. Particularly preferred is angiotensin III of the formula
Arg-Val-Tyr-Ile-His-Pro-Phe [SEQ ID NO:2]. Other preferred
compounds include peptides having the structures
Arg-Val-Tyr-Gly-His-Pro-Phe [SEQ ID NO:17] and
Arg-Val-Tyr-Ala-His-Pro-Phe [SEQ ID NO:18]. The fragment AII(4-8)
was ineffective in repeated tests; this is believed to be due to
the exposed tyrosine on the N-terminus.
[0050] In the above formulas, the standard three-letter
abbreviations for amino acid residues are employed. In the absence
of an indication to the contrary, the L-form of the amino acid is
intended. Other residues are abbreviated as follows:
1TABLE 1 Abbreviation for Amino Acids Me.sup.2Gly
N,N-dimethylglycyl Bet 1-carboxy-N,N,N-trimethylmethanaminium
hydroxide inner salt (betaine) Suc Succinyl Phe(Br)
p-bromo-L-phenylalanyl azaTyr aza-.alpha.'-homo-L-tyrosyl Acpc
1-aminocyclopentane carboxylic acid Aib 2-aminoisobutyric acid Sar
N-methylglycyl (sarcosine)
[0051] It has been suggested that AII and its analogues adopt
either a gamma or a beta turn (Regoli, et al., Pharmacological
Reviews 26:69 (1974). In general, it is believed that neutral side
chains in position R.sup.3, R.sup.5 and R.sup.7 may be involved in
maintaining the appropriate distance between active groups in
positions R.sup.4, R.sup.6 and R.sup.8 primarily responsible for
binding to receptors and/or intrinsic activity. Hydrophobic side
chains in positions R.sup.3, R.sup.5 and R.sup.8 may also play an
important role in the whole conformation of the peptide and/or
contribute to the formation of a hypothetical hydrophobic
pocket.
[0052] Appropriate side chains on the amino acid in position
R.sup.2 may contribute to affinity of the compounds for target
receptors and/or play an important role in the conformation of the
peptide. For this reason, Arg and Lys are particularly preferred as
R.sup.2.
[0053] For purposes of the present invention, it is believed that
R.sup.3 may be involved in the formation of linear or nonlinear
hydrogen bonds with R.sup.5 (in the gamma turn model) or R.sup.6
(in the beta turn model). R.sup.3 would also participate in the
first turn in a beta antiparallel structure (which has also been
proposed as a possible structure). In contrast to other positions
in general formula I, it appears that beta and gamma branching are
equally effective in this position. Moreover, a single hydrogen
bond may be sufficient to maintain a relatively stable
conformation. Accordingly, R.sup.3 may suitably be selected from
Val, Ala, Leu, norLeu, Ile, Gly, Pro, Aib, Acpc and Tyr.
[0054] With respect to R.sup.4, conformational analyses have
suggested that the side chain in this position (as well as in
R.sup.3 and R.sup.5) contribute to a hydrophobic cluster believed
to be essential for occupation and stimulation of receptors. Thus,
R.sup.4 is preferably selected from Tyr, Thr, Tyr (PO.sub.3).sub.2,
homoSer, Ser and azaTyr. In this position, Tyr is particularly
preferred as it may form a hydrogen bond with the receptor site
capable of accepting a hydrogen from the phenolic hydroxyl (Regoli,
et al. (1974), supra).
[0055] In position R.sup.5, an amino acid with a .beta. aliphatic
or alicyclic chain is particularly desirable. Therefore, while Gly
is suitable in position R.sup.5, it is preferred that the amino
acid in this position be selected from Ile, Ala, Leu, norLeu, Gly
and Val.
[0056] In the angiotensinogen, AI, AI analogues, AI fragments and
analogues thereof, AII analogues, fragments and analogues of
fragments of particular interest in accordance with the present
invention, R.sup.6 is His, Arg or 6-NH.sub.2-Phe. The unique
properties of the imidazole ring of histidine (e.g., ionization at
physiological pH, ability to act as proton donor or acceptor,
aromatic character) are believed to contribute to its particular
utility as R.sup.6. For example, conformational models suggest that
His may participate in hydrogen bond formation (in the beta model)
or in the second turn of the antiparallel structure by influencing
the orientation of R.sup.7. Similarly, it is presently considered
that R.sup.7 should be Pro in order to provide the most desirable
orientation of R.sup.8. In position R.sup.8, both a hydrophobic
ring and an anionic carboxyl terminal appear to be particularly
useful in binding of the analogues of interest to receptors;
therefore, Tyr and especially Phe are preferred for purposes of the
present invention.
[0057] Analogues of particular interest include the following:
2TABLE 2 Angiotensin II Analogues All Analogue Sequence Name Amino
Acid Sequence Identifier Analogue 1 Asp-Arg-Val-Tyr-Val-His-Pro-Phe
SEQ ID NO: 19 Analogue 2 Asn-Arg-Val-Tyr-Val-His-Pro-Phe SEQ ID NO:
20 Analogue 3 Ala-Pro-Gly-Asp-Arg-Ile-Tyr-Val-His-Pro-Phe SEQ ID
NO: 21 Analogue 4 Glu-Arg-Val-Tyr-Ile-His-Pro-Phe SEQ ID NO: 22
Analogue 5 Asp-Lys-Val-Tyr-Ile-His-Pro-Phe SEQ ID NO: 23 Analogue 6
Asp-Arg-Ala-Tyr-Ile-His-Pro-Phe SEQ ID NO: 24 Analogue 7
Asp-Arg-Val-Thr-Ile-His-Pro-Phe SEQ ID NO: 25 Analogue 8
Asp-Arg-Val-Tyr-Leu-His-Pro-Phe SEQ ID NO: 26 Analogue 9
Asp-Arg-Val-Tyr-Ile-Arg-Pro-Phe SEQ ID NO: 27 Analogue 10
Asp-Arg-Val-Tyr-Ile-His-Ala-Phe SEQ ID NO: 28 Analogue 11
Asp-Arg-Val-Tyr-Ile-His-Pro-Tyr SEQ ID NO: 29 Analogue 12
Pro-Arg-Val-Tyr-Ile-His-Pro-Phe SEQ ID NO: 30 Analogue 13
Asp-Arg-Pro-Tyr-Ile-His-Pro-Phe SEQ ID NO: 31 Analogue 14
Asp-Arg-Val-Tyr(Po.sub.3).sub.2-Ile-His-Pro-Phe SEQ ID NO: 32
Analogue 15 Asp-Arg-norLeu-Tyr-Ile-His-Pro-Phe SEQ ID NO: 33
Analogue 16 Asp-Arg-Val-Tyr-norLeu-His-Pro-Phe SEQ ID NO: 34
Analogue 17 Asp-Arg-Val-homoSer-Tyr-Ile-His-Pro-Phe SEQ ID NO:
35
[0058] The polypeptides of the instant invention may be synthesized
by any conventional method, including, but not limited to, those
set forth in J. M. Stewart and J. D. Young, Solid Phase Peptide
Synthesis, 2nd ed., Pierce Chemical Co., Rockford, m. (1984) and J.
Meienhofer, Hormonal Proteins and Peptides, Vol. 2, Academic Press,
New York, (1973) for solid phase synthesis and E. Schroder and K.
Lubke, The Peptides, Vol. 1, Academic Press, New York, (1965) for
solution synthesis. The disclosures of the foregoing treatises are
incorporated by reference herein.
[0059] In general, these methods involve the sequential addition of
protected amino acids to a growing peptide chain (U.S. Pat. No.
5,693,616, herein incorporated by reference in its entirety).
Normally, either the amino or carboxyl group of the first amino
acid and any reactive side chain group are protected. This
protected amino acid is then either attached to an inert solid
support, or utilized in solution, and the next amino acid in the
sequence, also suitably protected, is added under conditions
amenable to formation of the amide linkage. After all the desired
amino acids have been linked in the proper sequence, protecting
groups and any solid support are removed to afford the crude
polypeptide. The polypeptide is desalted and purified, preferably
chromatographically, to yield the final product.
[0060] Preferably, peptides are synthesized according to standard
solid-phase methodologies, such as may be performed on an Applied
Biosystems Model 430A peptide synthesizer (Applied Biosystems,
Foster City, Calif.), according to manufacturer's instructions.
Other methods of synthesizing peptides or peptidomimetics, either
by solid phase methodologies or in liquid phase, are well known to
those skilled in the art.
[0061] Although AII has been shown to increase the proliferation of
a number of cell types in vitro, it does not necessarily increase
the proliferation of all cell types. Studies have shown that AII
accelerates cellular proliferation through the production of
transforming growth factor .beta. (TGF.beta.) (Gibbons et al., J.
Clin. Invest. 90:456-461 (1992). Thus, since only PDGF is known to
be mitogenic for MSC, an ability of AII to effect MSC proliferation
would be unexpected. Furthermore, as Emerson (supra) has shown that
inclusion of TGF-.beta. in most expansion cultures resulted in a
decreased HPC and HLSC yield, it is unexpected that AII, through
the action of TGF-.beta., would be of benefit in such situations.
No studies have reported that AII has an effect on the
differentiation of either HPC or MSC.
[0062] In one aspect of the present invention, a method of
increasing in vitro and ex vivo HPC and HLSC proliferation by
exposure to angiotensinogen, angiotensin I (AI), AI analogues, AI
fragments and analogues thereof, angiotensin II (AII), AII
analogues, AII fragments or analogues thereof, or AII AT.sub.2 type
2 receptor agonists is disclosed. Experimental conditions for the
isolation, purification, ex vivo growth and in vivo mobilization of
HPC and HLSC have been reported (Berardi, et al., Blood
86(6):2123-2129, 1995; Fritsch, et al., Bone Marrow Transplantation
17:169-178, 1996; LaRochelle, et al., Nature Medicine 12:1329-1337,
1996; Traycoff, et al., Experimental Hematology 24:299-306, 1996;
Holyoake, et al., Blood 87:4589-4595, 1996; Lemieux, et al., Blood
86:1339-1347, 1995; Talmadge, et al., Bone Marrow Transplantation
17:101-109, 1996; Bodine, et al., Blood 88:89-97, 1996; all
references hereby incorporated by reference herein.)
[0063] In one embodiment of the invention, HPC are isolated from
bone marrow, peripheral blood or umbilical cord blood. HPC is then
selected for in these samples. HPC-enriched samples are cultured
under appropriate growth conditions, in the presence of
angiotensinogen, AI, AI analogues, AI fragments and analogues
thereof, AII, AII analogues, AII fragments and analogues thereof
and/or AII AT.sub.2 type 2 receptor agonists. HPC proliferation is
assessed at various time points during culture.
[0064] In a preferred embodiment, HPC and HLSC are isolated from
bone marrow aspirates from the posterior iliac crest (Caplan and
Haynesworth, U.S. Pat. No. 5,486,359). CD34.sup.+ HPC are isolated
from the aspirate by attaching a biotinylated monoclonal antibody
specific for CD34 (available from Becton Dickinson, Sunnyvale,
Calif., USA) to a streptavidin affinity column (Ceprate SC;
CellPro, Bothell, Wash., USA) and passing the aspirate through the
column, followed by appropriate column washing and stripping,
according to standard techniques in the art. CD34.sup.30 HPC are
suspended in culture medium and incubated in the presence of,
preferably, between about 0.1 ng/ml and about 1 mg/ml
angiotensinogen, AI, AI analogues, AI fragments and analogues
thereof, AII, AII analogues, AII fragments and analogues thereof
and/or AII AT.sub.2 type 2 receptor agonists., The cells are
expanded for a period of between 8 and 21 days and cellular
proliferation with accompanying differentiation is assessed via
phase microscopy following standard methylcellulose colony
formation assays (Berardi, et al., supra) at various points during
this time period. Similarly, "self-renewal" of HPC is assessed
periodically by reactivity to an antibody directed against
CD34.sup.+.
[0065] In a further preferred embodiment, HPC that have been
cultured in the presence of angiotensinogen, AI, AI analogues, AI
fragments and analogues thereof, AII, AII analogues, AII fragments
and analogues thereof and/or AII AT.sub.2 type 2 receptor agonists
are used for autologous transplantation, to reconstitute a depleted
hematopoietic system. Prior to transplantation, the cells are
rinsed to remove all traces of culture fluid, resuspended in an
appropriate medium and then pelleted and rinsed several times.
After the final rinse, the cells are resuspended at between
0.7.times.10.sup.6 and 50.times.10.sup.6 cells per ml in an
appropriate medium and reinfused into a subject through intravenous
infusions. Following transplantation, subject peripheral blood
samples are evaluated for increases in the number of HPC, HLSC, and
more mature blood cells at various time points by standard flow
cytometry and cell sorting techniques. (Talmadge, et al.,
supra).
[0066] In another aspect of the present invention, a method of
increasing in vitro and ex vivo MSC and lineage-specific
mesenchymal cell proliferation by exposure to angiotensinogen, AI,
AI analogues, AI fragments and analogues thereof, AII, AII
analogues, AII fragments and analogues thereof and/or AII AT.sub.2
type 2 receptor agonists is disclosed. Experimental conditions for
the isolation, purification and in vitro growth of lineage-specific
mesenchymal cells, such as bone-marrow derived stromal cells, have
been reported (Johnson and Dorshkind, Blood 68(6):1348-1354 (1986);
hereby incorporated by reference in its entirety). Other reports
describe different conditions for culturing lineage-specific
mesenchymal cells in vitro (Bab, et al., J. Cell Sci. 84:139-151
(1986); Benayahu, et al., J. Cellular Physiology 140:1-7 (1989);
both references hereby incorporated by reference in their
entirety).
[0067] In one embodiment of the present invention, MSC are isolated
from bone marrow aspirates from the posterior iliac crest and/or
femoral head cancellous bone, purified, resuspended in appropriate
growth medium, counted and diluted to an appropriate concentration
to seed in tissue culture plates (Caplan and Haynesworth, U.S. Pat.
No. 5,486,359). Purified MSC are cultured in an appropriate growth
medium and growth conditions in a humidified atmosphere. The cells
are allowed sufficient time to attach to the tissue culture dish,
whereupon non-attached cells are discarded. Adherent cells are
placed in growth medium at 37.degree. C. in a humidified atmosphere
in the presence of, preferably, between about 0.1 ng/ml and about 1
mg/ml angiotensinogen, AI, AI analogues, AI fragments and analogues
thereof, AII, AII analogues, AII fragments and analogues thereof
and/or AII AT.sub.2 type 2 receptor agonists. The cells are
expanded for a period of between 2 and 21 days and cellular
proliferation is assessed at various time points during this time
period. Subsequent medium changes are performed as needed. When the
primary cultures are nearly confluent, the cells are harvested for
reinfusion into a subject. Cells are examined microscopically to
verify the absence of contamination. The cells are rinsed to remove
all traces of culture fluid, resuspended in an appropriate medium
and then pelleted and rinsed several times. After the final rinse,
the cells are resuspended at between 0.7.times.10.sup.6 and
50.times.10.sup.6 cells per ml in an appropriate medium and
reinfused into a subject through intravenous infusions. Subjects
are evaluated for MSC proliferation in vivo by means of a repeat
diagnostic bone marrow aspirate and biopsy to be compared with the
original aspirate and biopsy. In a preferred embodiment, in vivo
proliferation is assessed by reactivity to an antibody directed
against a protein known to be present in higher concentrations in
proliferating cells than in non-proliferating cells, such as
proliferating cell nuclear antigen (PCNA, or cyclin). Such
antibodies are commercially available from a number of sources,
including Zymed Laboratories (South San Francisco, Calif.,
USA).
[0068] In a preferred embodiment, isolated MSC, are placed into
Dulbecco's medium MEM (DMEM-LG) (Gibco, Grand Island, N.Y., USA).
The cells are purified by a series of steps. Initially, the cells
are pelleted and resuspended in Complete Medium. The cells are
centrifuged through a 70% Percoll (Sigma Corporation, St. Louis,
Mo., USA) gradient at 460.times.g for 15 minutes, the top 25% of
the gradients are transferred to a tube containing 30 ml of
Complete Medium and centrifuged to pellet the cells, which will
then be resuspended in Complete Medium, counted and diluted to seed
in 100-mm plates at 50.times.10.sup.6 nucleated cells per
plate.
[0069] In a further preferred embodiment, purified MSC are cultured
in Complete Medium at 37.degree. C. in a humidified atmosphere
containing 95% air and 5% CO.sub.2 and the cells are allowed to
attach for 3 days, whereupon non-adherent cells are removed by
changing the culture medium. Cellular proliferation of adherent
cells and the presence of normal MSC morpholgy are assessed by
phase microscopy at various time points during the subsequent
growth period. Subsequent medium changes are performed every four
days. When the primary cultures are nearly confluent, the cells are
detached with 0.25% trypsin containing 0.1 mM EDTA (Gibco) and
either diluted and replated as second passage cells, or used for
reinfusion into a subject. Preferably, cells are rinsed free of
culture fluid using Tyrode's solution (Gibco). After the final
rinse, cells are placed in Tyrode's solution and placed in an
incubator at 37.degree. C. for one hour in order to shed serum
proteins. The Tyrode's solution is removed and the cells are
preferably placed into TC199 medium (Gibco) supplemented with 1%
serum albumin. The cells are rinsed a number of times with this
medium and after the final rinse MSC are resuspended in TC199 plus
1% serum albumin. Subsequently, MSC are injected slowly
intravenously over 15 minutes. Evaluation of subsequent bone marrow
aspirates are conducted up to 8 weeks after injection.
[0070] In a preferred embodiment, assessment of the in vivo
proliferative effect (of angiotensinogen, AI, AI analogues, AI
fragments and analogues thereof, AII, AII analogues, AII fragments
and analogues thereof and/or AII AT.sub.2 type 2 receptor agonists
on MSC and mesenchymal lineage-specific cells is done by
histochemical evaluations of various tissues. In a preferred
embodiment, in vivo proliferation of MSC and mesenchymal
lineage-specific cells is assessed by reactivity to an antibody
directed against a protein known to be present in higher
concentrations in proliferating cells than in non-proliferating
cells, such as proliferating cell nuclear antigen (PCNA, or cyclin;
Zymed Laboratories).
[0071] In a further aspect of the present invention, the effect of
angiotensinogen, AI, AI analogues, AI fragments and analogues
thereof, AII, AII analogues, AII fragments and analogues thereof
and/or AII AT.sub.2 type 2 receptor agonists on HPC, HLSC
differentiation are assessed by examination of changes in gene
expression, phenotype, morphology, or any other method that
distinguishes a cell undergoing differentiation from a
lineage-specific cell. In a preferred embodiment, macrophage
differentiation to an elicited or activated state is assessed after
exposure to angiotensinogen, AI, AI analogues, AI fragments and
analogues thereof, AII, AII analogues, AII fragments and analogues
thereof and/or AII AT.sub.2 type 2 receptor agonists, as described
above. The macrophages are assessed for phagocytotic ability by any
of the well known art methods, including but not limited to
determination of the number of macrophages that have ingested
opsonized yeast particles, and the number of yeast per macrophage
ingested. (Rodgers and Xiong, Fundamental and Applied Toxicology
33:100-108 (1996)).
[0072] In another preferred embodiment, the respiratory burst
activity of leukocytes is assessed after exposure to
angiotensinogen, AI, AI analogues, AI fragments and analogues
thereof, AII, AII analogues, AII fragments and analogues thereof
and/or AII AT.sub.2 type 2 receptor agonists as described above.
The leukocytes are assessed for respiratory burst activity by any
method; known in the art including, but not limited to, the ability
to generate hydrogen peroxide via the respiratory burst system.
(Rodgers et al., International Journal of Immunopharmacology
10:111-120 (1988); Rodgers, In: Modern Methods in Immunotoxicology
(ed. G. Burleson), Wiley Liss 2:67-77 (1995)).
[0073] Macrophage activation by the compounds of the present
invention can be utilized for treating viral and microbial
infections, stimulating macrophages to produce cytokines made by
activated macrophages, improving macrophage presentation to T
cells, and augmenting anti-tumor immunity in a mammal.
[0074] In another aspect of the present invention angiotensinogen,
AI, AI analogues, AI fragments and analogues thereof, AII, AII
analogues, AII fragments and analogues thereof and/or. AII AT.sub.2
type 2 receptor agonists are used to increase in vivo HPC, HLSC,
MSC and mesenchymal lineage-specific cell proliferation. For use in
increasing proliferation of HPC, HLSCP, MSC and mesenchymal
lineage-specific cells, angiotensinogen, AI, AI analogues, AI
fragments and analogues thereof, AII, AII analogues, AII fragments
and analogues thereof and/or AII AT.sub.2 type 2 receptor agonists
may be administered by any suitable route, including orally,
parentally, by inhalation spray, rectally, or topically in dosage
unit formulations containing conventional pharmaceutically
acceptable carriers, adjuvants, and vehicles. The term parenteral
as used herein includes, subcutaneous, intravenous, imtramuscular,
intrasternal, intratendinous, intraspinal, intracranial,
intrathoracic, infusion techniques or intraperitoneally.
[0075] In a further embodiment of the present invention, a method
of increasing in vivo HPC, HLSC, MSC and lineage-specific
mesenchymal cell proliferation by exposure to angiotensinogen, AI,
AI analogues, AI fragments and analogues thereof, AII, AII
analogues, AI fragments and analogues thereof and/or AII AT.sub.2
type 2 receptor agonists is disclosed, either in the presence or
absence of other growth factors and cytokines. Examples of such
growth factors and cytokines include, but are not limited to
lymphokines, interleukins-1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,
granulocyte colony-stimulating factor, granulocyte/macrophage
colony stimulating factor, macrophage colony-stimulating factor,
tumor necrosis factor, epidermal growth factor, fibroblast growth
factor, platelet derived growth factor, transforming growth factor
beta, and stem cell factor.
[0076] The angiotensinogen, AI, AI analogues, AI fragments and
analogues thereof, AII, AII analogues, AII fragments and analogues
thereof and/or AII AT.sub.2 type 2 receptor agonists may be made up
in a solid form (including granules, powders or suppositories) or
in a liquid form (e.g., solutions, suspensions, or emulsions). The
compounds of the invention may be applied in a variety of
solutions. Suitable solutions for use in accordance with the
invention are sterile, dissolve sufficient amounts of the peptide,
and are not harmful for the proposed application. In this regard,
the compounds of the present invention are very stable but are
hydrolyzed by strong acids and bases. The compounds of the present
invention are soluble in organic solvents and in aqueous solutions
at pH 5-8.
[0077] The angiotensinogen, AI, AI analogues, AI fragments and
analogues thereof, AII, AII analogues, AII fragments and analogues
thereof and/or AII AT.sub.2 type 2 receptor agonists may be
subjected to conventional pharmaceutical operations such as
sterilization and/or may contain conventional adjuvants, such as
preservatives, stabilizers, wetting agents, emulsifiers, buffers
etc. * While angiotensinogen, AI, AI analogues, AI fragments and
analogues thereof, AII, AII analogues, AII fragments and analogues
thereof and/or AII AT.sub.2 type 2 receptor agonists can be
administered as the sole active pharmaceutical agent, they can also
be used in combination with one or more other agents. When
administered as a combination, the therapeutic agents can be
formulated as separate compositions that are given at the same time
or different times, or the therapeutic agents can be given as a
single composition.
[0078] For administration, the angiotensinogen, AI, AI analogues,
AI fragments and analogues thereof, AII, AII analogues, AII
fragments and analogues thereof and/or AII AT.sub.2 type 2 receptor
agonists are ordinarily combined with one or more adjuvants
appropriate for the indicated route of administration. The
compounds may be admixed with lactose, sucrose, starch powder,
cellulose esters of alkanoic acids, stearic acid, talc, magnesium
stearate, magnesium oxide, sodium and calcium salts of phosphoric
and sulphuric acids, acacia, gelatin, sodium alginate,
polyvinylpyrrolidine, and/or polyvinyl alcohol, and tableted or
encapsulated for conventional administration. Alternatively, the
compounds of this invention may be dissolved in saline, water,
polyethylene glycol, propylene glycol, carboxymethyl cellulose
colloidal solutions, ethanol, corn oil, peanut oil cottonseed oil,
sesame oil, tragacanth gum, and/or various buffers. Other adjuvants
and modes of administration are well known in the pharmaceutical
art. The carrier or diluent may include time delay material, such
as glyceryl monostearate or glyceryl distearate alone or with a
wax, or other materials well known in the art.
[0079] Formulations suitable for topical administration include
liquid or semi-liquid preparations suitable for penetration through
the skin (e.g., liniments, lotions, ointments, creams, or pastes)
and drops suitable for administration to the eye, ear, or nose.
[0080] The dosage regimen for increasing in vivo proliferation or
differentiation of HPC, HLSCP, MSC and lineage-specific mesenchymal
cell with angiotensinogen, AI, AI analogues, AI fragments and
analogues thereof, AII, AII analogues, AII fragments and analogues
thereof and/or AII AT.sub.2 type 2 receptor agonists is based on a
variety of factors, including the type of injury, the age, weight,
sex, medical condition of the individual, the severity of the
condition, the route of administration, and the particular compound
employed. Thus, the dosage regimen may vary widely, but can be
determined; routinely by a physician using standard methods. Dosage
levels of the order of between 0.1 ng/kg and 1 mg/kg
angiotensinogen, AI, AI analogues, AI fragments and analogues
thereof, AII, AII analogues, AII fragments and analogues thereof
and/or AII AT.sub.2 type 2 receptor agonists per body weight are
useful for all methods of use disclosed herein.
[0081] The treatment regime will vary depending on the disease
being treated, based on a variety of factors, including the type of
injury, the age, weight, sex, medical condition of the individual,
the severity of the condition, the route of administration, and the
particular compound employed. For example, angiotensinogen, AI, AI
analogues, AI fragments and analogues thereof, AII, AII analogues,
AII fragments and analogues thereof and/or AII AT.sub.2 type 2
receptor agonists are administered to an oncology patient for up to
30 days prior to a course of radiation therapy. The therapy is
administered for 1 to 6 times per day at dosages as described,
above. In another example, in order to mobilize, hematopoietic
lineage-specific cells for donation by plasmapheresis the therapy
is for up to 30 days for 1 to 6 times per day.
[0082] In a preferred embodiment of the present invention, the
angiotensinogen, AI, AI analogues, AI fragments and analogues
thereof, AII, AII analogues, AII fragments and analogues thereof
and/or AII AT.sub.2 type 2 receptor agonist is administered
topically. A suitable topical dose of active ingredient of
angiotensinogen, AI, AI analogues; AI fragments and analogues
thereof, AII, AII analogues, AII fragments and analogues thereof
and/or AII AT.sub.2 type 2 receptor agonists is preferably between
about 0.1 ng/ml and about 1 mg/ml administered twice daily. For
topical administration, the active ingredient may comprise from
0.0001% to 10% w/w, e.g., from 1% to 2% by weight of the
formulation, although it may comprise as much as 10% w/w, but
preferably not more than 5% w/w, and more preferably from 0.1% to
1% of the formulation.
[0083] In another aspect of the present invention, an improved cell
culture medium is provided for the proliferation and
differentiation of hematopoietic and mesenchymal stem and
lineage-specific cells, wherein the improvement comprises addition
to the cell culture medium of an effective amount of
angiotensinogen, AI, AI analogues, AI fragments and analogues
thereof, AII, AII analogues, AII fragments and analogues thereof
and/or AII AT.sub.2 type 2 receptor agonists, as described above.
Any cell culture media that can support the growth of hematopoietic
and mesenchymal stem and lineage-specific cells can be used with
the present invention. Such cell culture media include, but are not
limited to Basal Media Eagle, Dulbecco's Modified Eagle Medium,
Iscove's Modified Dulbecco's Medium, McCoy's Medium, Minimum
Essential Medium, F-10 Nutrient Mixtures, Opti-MEMO Reduced-Serum
Medium, RPMI Medium, and Macrophage-SFM Medium or combinations
thereof The improved cell culture medium can be supplied in either
a concentrated (ie: 10.times.) or non-concentrated form, and may be
supplied as either a liquid, a powder, or a lyophilizate. The cell
culture may be either chemically defined, or may contain a serum
supplement. Culture media is commercially available from many
sources, such as GIBCO BRL (Gaithersburg, Md.) and Sigma (St.
Louis, Mo.)
[0084] In a further aspect, the present invention provides kits for
the propagation of hematopoietic and mesenchymal stem and
lineage-specific cells, wherein the kits comprise an effective
amount of angiotensinogen, AI, AI analogues, AI fragments and
analogues thereof, AII, AII analogues, AII fragments and analogues
thereof and/or AII AT.sub.2 type 2 receptor agonists, and
instructions for its use as a cell culture media supplement.
[0085] In a preferred embodiment, the kits further comprise cell
culture growth medium. Any cell culture media that can support the
growth of hematopoietic and mesenchymal stem and lineage-specific
cells can be used with the present invention. Examples of such cell
culture media are described above. The cell culture medium can be
supplied in either a concentrated (ie: 10.times.) or
non-concentrated form, and may be supplied as either a liquid, a
powder, or a lyophalizate. The cell culture may be either
chemically defined, or may contain a serum supplement.
[0086] In a further preferred embodiment, the kit further comprises
a sterile container, which can comprise either a sealed container,
such as a cell culture flask, a roller bottle, or a centrifuge
tube, or a non-sealed container, such as a cell culture plate or
microtiter plate (Nunc; Naperville, Ill.).
[0087] In another preferred embodiment, the kit further comprises
an antibiotic supplement for inclusion in the reconstituted cell
growth medium. Examples of appropriate antibiotic supplements
include, but are not limited to actimonycin D, Fungizone.RTM.,
kanamycin, neomycin, nystatin, penicillin, streptomycin, or
combinations thereof (GIBCO).
[0088] The present invention, by providing a method for enhanced
proliferation of HPC and HLSC, will greatly increase the clinical
benefits of HPC transplantation. This is true both for increased
"self-renewal", which will provide a larger supply of PC capable of
reconstituting the entire hematopoietic system, and for
proliferation with differentiation, which will provide a larger
supply of lineage-specific cells, for more rapid reconstitution of
mature, functioning blood cells. Similarly, methods that increase
in vivo proliferation of HPC will enhance the utility of HPC
transplantation therapy by rapidly increasing local concentrations
of HPC (and HLSC) in the bone marrow, and thereby more rapidly
producing functioning blood cells.
[0089] Similarly, methods that increase the proliferation of MSC
and mesenchymal lineage-specific cells, will greatly increase the
utility of MSC therapy in the repair of skeletal tissues such as
bone, cartilage, tendon and ligament. More rapid proliferation of
large numbers of MSC and mesenchymal lineage-specific cells will
permit more efficient delivery of high densities of these cells to
a defect site and more rapid in vivo amplification in the local
concentration of stem and lineage-specific cells at an appropriate
repair site.
[0090] The method of the present invention also increases the
potential utility of HPC and HLSC as vehicles for gene therapy in
hematopoietic disorders, as well as MSC and mesenchymal
lineage-specific cells as vehicles for gene therapy in skeletal
disorders by more efficiently providing a large number of such
cells for transfection, and also by providing a more efficient
means to rapidly expand transfected HPC, HLSC, MSC and mesenchymal
lineage-specific cells.
[0091] The present invention may be better understood with
reference to the accompanying examples that are intended for
purposes of illustration only and should not be construed to limit
the scope of the invention, as defined by the claims appended
hereto.
EXAMPLE 1
Macrophage Differentiation: Phagocytosis
[0092] Resident peritoneal macrophages have very little phagocytic
activity. Exposure of macrophages to inflammatory or activating
agents will increase this macrophage function. Resident peritoneal
macrophages were harvested from C57B1/6 mice or Sprague Dawley rats
and resuspended at a concentration of 1.times.10.sup.6 cells/ml. in
phosphate buffered saline (PBS). Five separate 0.5 ml cell aliquots
were placed on a glass coverslip in a 35 mm petri dish. Prior to
incubation, either 0.5 ml of PBS, AII, or AII analogues or
fragments at between 1-1000 ug/ml final concentration was added to
the individual cover slips. The dishes containing the cover slips
were then incubated at 37.degree. C. for 4 hours, after which the
cover slips were washed 3 to 6 times with PBS. Opsonized yeast
particles (Sigma Chemical Co.) (yeast opsonized with adult serum
from the same species as that under study) were added to the cover
slips and incubated for 2 hours, after which the cover slips were
again washed with PBS and inverted onto a glass slide. The number
of macrophages that ingested yeast and the number of yeast per
macrophage ingested was then determined microscopically. At least
100 macrophages per coverslip were counted. The data from this
study are summarized in Tables 3 and 4 and FIGS. 1 and 2. Table 5
describes the AII analogues and fragments used in these
studies.
[0093] Exposure to 10 .mu.g/ml or greater AII tremendously
increased the phagocytic capability of peritoneal macrophages. Less
than 1% of cells were phagocytic in the resident population (0.01
yeast per cell observed). After exposure to AII this increased to
over 25% phagocytic at the highest concentration with on average 1
yeast observed per macrophage (25 fold increase in the number of
macrophages able to phagocytose and a 100-fold increase in the
number of particles phagocytized).
[0094] As shown in Table 4, both concentration of the peptides
tested (with the exception of GSD 28) elevated that phagocytic
capability of rat macrophages. However, none of the analogues
resulted in the magnitude of an effect observed with AII. This
suggests that AII and, to a lesser extent, AII analogues will
stimulate macrophage differentiation to an elicited or activated
state, which leads to the ingestion and clearance of bacteria and
cellular debris.
3TABLE 1 Effect of All on the Phagocytic Capability of Murine
Peritoneal Macrophages Concentration of All (.mu.g/ml) 0 1 10 100
1000 Yeast # # Macrophages with Yeast 0 100 100 100 100 100 1-3 1 1
3 10 20 4-6 0 0 4 10 20 7-9 0 0 0 0 0 % Ingesting 1 1 6.5 16.7 25.6
# Yeast/MO 0.01 0.01 0.24 0.58 1.00
[0095]
4TABLE 4 Effect of AII on the Phagocytic Capability of Rat
Peritoneal Macrophages Number of Macrophages with Yeast (Peptide)
(Yeast Number) .mu.g/ml 0 1-3 4-6 .gtoreq.7 % w/Yeast #/Cell AII-0
88 2 0 0 2.2 0.04 100 90 30 20 0 35.7 1.14 1000 50 54 40 25 70.4
2.86 AII (1-7)-0 90 3 0 0 3.2 0.06 100 100 21 5 0 20.6 0.53 1000 90
30 10 0 30.8 0.85 GSD22A-0 90 1 0 0 1.1 0.02 100 100 26 5 0 23.7
0.59 1000 100 22 1 0 18.7 0.40 GSD 24-B-0 100 2 0 0 2.0 0.04 100
100 25 5 0 23.1 0.58 1000 100 10 0 0 9.1 0.18 GSD28-0 100 1 0 0 1.0
0.02 100 100 1 0 0 1.0 0.02 1000 100 1 0 0 1.0 0.02
[0096]
5TABLE 5 Designation for Analogues Name Abbreviation Sequence GSD
28 Ile.sup.8-AII DRVYIHPI GSD 24B Pro.sup.3-AII DRPYLHPF GSD 22A
Ala.sup.4-AII RVYAHPF AII(1-7) DRVYIHP
EXAMPLE 2
Leukocyte Differentiation: Respiratory Burst
[0097] The respiratory burst of leukocytes (macrophages and
polymorphonuclear neutrophils) is one component of the mediator
system used to kill bacteria. As with phagocytosis, the level of
this respiratory burst activity in resident macrophages is low.
With differentiation, either to an elicited (inflammatory) or
activated state, this functional activity is significantly
elevated. Studies were conducted to assess the effect of in vitro
exposure of murine or rat peritoneal macrophages and human
peripheral blood mononuclear cells, (PBMC) to various
concentrations of AII on the capacity to generate hydrogen peroxide
via the respiratory burst system. For the human studies, five
different donors were examined.
[0098] The murine or rat peritoneal cells were harvested by lavage
with 5-15 ml of cold PBS with 0.5% bovine serum albumin. The human
PBMC were harvested by venipuncture from normal human volunteers
and isolated from peripheral blood by Ficoll Hypaque density
centrifugation. After isolation, the cells were resuspended at
1.times.10.sup.6 cells/ml and placed at 100 .mu.l per well into 96
well plates. The cells were incubated with various concentrations
of AII or AII analogues for 4 hours at 37.degree. C. The cells were
then preloaded with a fluorescent probe for hydrogen peroxide, 2,7
dichlorofluorescein acetate, which is nonfluorescent in the absence
of hydrogen peroxide. Fifteen minutes later, 10 ng/ml of phorbol
myristate acetate (+PMA) or PBS (-PMA) was added to stimulate the
production of hydrogen peroxide. One hour after stimulation the
level of fluorescence produced was measured on a Cytofluor 2350
multiwell fluorometer. Representative results from this study are
shown in FIGS. 3-4.
[0099] In the absence of PMA or peptide, no hydrogen peroxide
production is observed. Some variability in the response to AII was
seen (i.e. the concentration of AII necessary to increase the level
of this function); however, in all studies AII increased the
ability of leukocytes to generate hydrogen peroxide both alone and
in response to stimulation with PMA. Further, the effect of
pre-exposure to analogues of AII (GSD 22A, GSD 24B, GSD 28 and
AII(1-7)) on the respiratory burst activity of PBMC was assessed
(FIGS. 5-8). For all analogues, a much higher concentration of the
peptide was needed to increase the respiratory burst activity. Up
to 100 times more of these analogues were necessary; however, an
increase in the respiratory burst capacity was observed for all
analogues tested. The analogues were able to stimulate that
function both in the presence and absence of PMA. These data
indicate that AII was able to stimulate the differentiation of
monocytes/macrophages from three species.
EXAMPLE 3
Proliferative Response of Human Lymphocytes
[0100] Upon stimulation of lymphocytes with mitogen or antigen,
these cells undergo blastogenesis and proliferation. In the absence
of such stimuli, proliferation is seldom observed. One method to
measure cellular proliferation in a short term assay is via
measurement of the amount of the nucleotide thymidine that is
incorporated into newly synthesized DNA. The effect of AII on the
proliferation of human PBMC in the presence and absence of pokeweed
mitogen ("PWM") was assessed.
[0101] Human PBMC were collected from normal volunteers and
isolated via Ficoll Hypaque (Sigma Chemical, St. Louis) density
centrifugation. After isolation of the buffy coat, the cells were
washed 3.times. to remove the Ficoll Hypaque, counted in trypan
blue (0.01%) and resuspended at a concentration of 1.times.10.sup.6
cells/ml in RPMI 1640 containing 10% fetal calf serum and
antibiotics. A 100 .mu.l aliquot of cells was added to each well.
Thereafter, various concentrations (0.1 to -1000 .mu.g/ml final
concentration) of AII in RPMI 1640 containing 10% FCS and
antibiotics were added to various wells in triplicate. To the
appropriate wells, PWM (20 .mu.g/ml final concentration) was added.
These plates were incubated at 37.degree. C. in 5% CO.sub.2 for 48
hours. Subsequently, 0.5 .mu.Ci of .sup.3H-thymidine was added to
each well, which were incubated at 37.degree. C. for an additional
24 hours prior to harvest by a multiwell automated sample harvester
(Skatron) onto glass fiber filters. These filters were dried,
placed in scintillation fluid and the amount of thymidine
incorporated was determined by beta counting. The results are shown
in FIG. 9 and Table 6.
[0102] In the absence of mitogen, no increase in thymidine
incorporation was observed after exposure to AII. However, in two
separate experiments (cells from 2 different donors) AII was shown
to increase the amount of thymidine incorporated in response to
PWM. These data show that AII is able to increase the proliferation
of cells from the hematopoietic lineage (e.g. lymphocytes).
6TABLE 6 Effect of AII on the Proliferation of Human PBMC
Proliferation Index cpm .sup.3H-Thymidine Incorporated (SI.sup.a)
AII Concentration Experiment 1.sup.b Experiment 2 0 1146.3 (3.63)
2022.0 (31.11) 0.1 1329.0 (3.54) 2135.0 (38.13) 1 1411.2 (5.88)
2996.0 (62.42) 10 1427.0 (5.34) 3946.0 (75.88) 100 1552.1 (11.41)
3747.0 (69.39) 1000 1551.5 (15.48) 4302.0 (89.63) .sup.aSI =
Stimulation Index is calculated from the ration of the counts
incorporated into stimulated cultures divided by counts in cultures
without mitogen (FCS only-basal proliferation). This is shown in
the parentheses. .sup.bThe effect of AII on the proliferation of
PBMC from two separate donors are shown in this table.
EXAMPLE 4
Rat Mesenchymal Stem Cell Proliferation
[0103] These studies were conducted to determine the effect that
AII would have on the proliferation of MSC. Bone marrow cells were
harvested from the femur and tibia of female Sprague Dawley rats by
flushing the bones with Dulbecco's Minimal Essential Medium-High
Glucose ("DMEM-HG") with a syringe and an 18 gauge needle. These
cells were cultured in 24 well plates at 5.times.10.sup.3
cells/mm.sup.2 in DMEM-HG containing selected lots of fetal calf
serum (FCS) and antibiotics (complete medium) at 37?C incubator
containing 5% CO.sub.2 in air. Twenty-four hours after the
initiation of the cultures the medium and nonadherent cells were
aspirated and fresh medium was added. To each of these several
wells, complete medium with (1 to 100 .mu.g/ml) or without AII was
added. The migration of cells from the clones and their
proliferation was followed by microscopic examination. Every 4 days
the old medium was removed and fresh medium was added to the
cultures.
[0104] The data from these experiments are shown in FIGS. 10 and
11. Addition of AII to the cultures significantly increased the
number of sites from which the MSC were migrating (CFU) and the
size (number of cells) of the colonies formed. This occurred only
in the presence of serum that in itself would support MSC growth,
albeit to a lesser extent. As can be seen, AII caused an increase
in the number of MSC in a concentration dependent manner at all
time points examined in the presence of two different serum lots.
These data support the hypothesis that AII can increase the
proliferation of rat MSC.
EXAMPLE 5
Effect of Angiotensin II on Murine Lineage-Specific Cells
[0105] HPC were harvested from C57B1/6 mice by immunomagnetic
affinity chromatography and placed in semi-solid cultures with
optimal growth medium. At various times after initiation of
culture, the formation of colonies and the size of the colonies
(number of cells/colony) was assessed microscopically.
[0106] Female C57B1/6 mice were purchased from Simonson and used as
a source of bone marrow cells in this study. The bone marrow was
harvested, either from untreated mice or from mice injected with
5-fluorouracil,(5-FU) (3 mg/mouse; approximately 150 mg/kg) in the
tail vein 48 hours before harvest, from the femur and tibia of mice
by flushing with phosphate buffered saline (PBS), pH 7.4,
containing 2% fetal bovine serum (FBS) with a 21-gauge needle. The
eluant from the flushing was centrifuged and the pellet was
resuspended at 4.times.10.sup.7 nucleated cells/ml in PBS
containing PBS containing 2% FBS and 5% normal rat serum.
[0107] The reagents for immunomagnetic labeling were purchased from
Stem Cell Technologies, Inc. (Vancouver, BC). Biotin-labeled
monoclonal antibodies to the following murine lineage-specific cell
surface antigens were included in a cocktail for HPC enrichment and
used according to the manufacturer's instructions: CD5 (Ly-1),
CD45-R (B220), CD11b (Mac-1), Myeloid Differentiation Antigen
(Gr-1) and Erythroid Cells (TER 119) Ten .mu.l of antibody cocktail
was added for each of the 2 sets of bone marrow (normal and
5-FU-treated), mixed and allowed to incubate at 4.degree. C. for 15
minutes. The cells were then resuspended at 4.times.10.sup.7
cells/ml in PBS containing 2% FBS. The antibody cocktail was then
washed out and 100 .mu.l anti-biotin tetramer was added for each ml
of cells. The suspension was mixed and incubated at 4.degree. C.
for 15 minutes. Sixty .mu.l of magnetic colloid was then added for
each ml of cells, the combination was mixed and incubated at
4.degree. C. for 15 minutes to yield the immunomagnetically-labeled
bone marrow cells.
[0108] A column containing a stainless steel matrix was prepared by
washing the matrix with PBS followed by washing with PBS containing
2% protein. The immunomagnetically-labeled bone marrow cells were
loaded onto the column and unlabeled cell-containing medium
(enriched HPC) was collected in the flow through fraction at a flow
rate of 0.2 ml/minute. Medium was added to the top of the column so
that it did not run dry until 8 to 10 ml of enriched HPC were
harvested. Approximately 2% of the cells loaded onto the column
were isolated-in the enriched HPC fractions.
[0109] The enriched HPC cell fractions were diluted into a
semi-solid medium containing 0.9% methylcellulose in alpha minimal
essential medium (alpha MEM), 30% fetal calf serum, 1% bovine serum
albumin, 10.sup.-4 M 2-mercaptoethanol, 2 mM L-glutamine, and 2%
conditioned medium containing colony stimulating factors. The
conditioned medium was supernatant from splenocyte cultures
(1.times.10.sup.6 cells/ml) incubated for 48 hours in RPMI 1640
containing 10 .mu.g/ml pokeweed mitogen (PWM), 10% FCS, and
antibiotics. Various concentrations of AII, between 0 and 100
.mu.g/ml were added in a small volume to the wells of microtiter
dishes, to which between 2.times.110 cells/ml for the normal and
2.5.times.10.sup.4 cells/ml for the 5-FU treated cells. The cells
were incubated at 37.degree. C. and 5% CO.sub.2 for 14 days. At day
14 only, macroscopic cell colonies were observed in the wells
containing enriched HPC from untreated (normal) mice treated with
10 .mu.g/ml (18 macroscopic colonies) and 100 .mu.g/ml AII (10
macroscopic colonies). Microscopic evaluation of the cells was
performed at various days after initiation of incubation, and the
results are summarized in FIGS. 12-17.
[0110] FIGS. 12-14 and 16 represent the number of colonies
containing more than a certain number of cells/colony as a function
of the duration and concentration of AII exposure (FIGS. 12-14 for
normal cells; FIG. 16 for 5-FU treated cells.) FIGS. 15 and 17
represents the number of cells per colony seen after incubation of
bone marrow from normal or 5-FU treated mice with various
concentrations of AII as a function of time. The results clearly
demonstrate that HPC colony size increases proportionately with
exposure to increased concentrations of AII, and thus that AII
increases HPC proliferation.
EXAMPLE 6
Effect of AII Analogues and Fragments on Rat Mesenchymal Stem Cell
Proliferation
[0111] These studies were conducted to determine the effect that
inclusion of AII analogues and fragments in the cell culture of MSC
would have on the proliferation of these cells. Bone marrow cells
were harvested from the femur and tibia of female Sprague Dawley
rats by flushing the bones with Dulbecco's Minimal Essential
Medium-High Glucose ("DMEM-HG") with a syringe and an 18 gauge
needle. These cells were cultured in 24 well plates at 5.times.10
cells/mm.sup.2 in DMEM-HG containing selected lots of fetal calf
serum (FCS) and antibiotics (complete medium) at 37.degree. C.
incubator containing 5% CO.sub.2 in air. Twenty-four hours after
the initiation of the cultures the medium and nonadherent cells
were aspirated and fresh medium was added. To each of these several
wells, complete medium with (1 to 100 .mu.g/ml) or without AII
analogues and fragments (see Table 5) was added. The migration of
cells from the clones and their proliferation was followed by
microscopic examination. Every. 4 days the old medium was removed
and fresh medium was added to the cultures.
[0112] Addition of AII analogues or AII fragments to these cultures
had a profound effect on the number of sites from which MSC were
migrating (CFU) and the size (number of cells) of the colonies
formed. The results from these studies can be seen in FIGS. 18-21.
As can be seen, AII analogues and fragments caused an increase in
the number of MSC at all time points examined. These data indicate
that AI analogues and fragments can increase the proliferation of
rat MSC.
EXAMPLE 7
Proliferation of MSC Lineage-Specific Cells in the Presence of
AII
[0113] Mesenchymal stem cells isolated from bone marrow and grown
under appropriate conditions can express characteristics of
multiple cell types, including cells involved in the aspiration of
bone, cartilage, muscle and tendons. Osteogenic cells (cells that
can form bone tissue) express the enzyme alkaline phosphatase when
cultured in medium that drives them toward their osteogenic
differentiation.
[0114] Bone marrow from female Sprague Dawley rats were harvested
by flushing the femur with medium. The cells were placed in culture
dishes 9 cm.sup.2 in diameter, allowed to adhere overnight, and
then placed in DMEM-LG medium containing antibiotics and 10% fetal
calf serum together with varying concentrations of AII. At various
times after culture initiation, the cells were washed with Tyrode's
buffer and placed in osteogenic medium (DMEM-LG containing 10%
fetal calf serum, 100 nM dexamethasone and 0.05 mM ascorbic acid)
for 4 days prior to assessment of the level of alkaline phosphatase
activity per well. Briefly, the wells were washed with Tyrode's
buffer and 1 ml alkaline phosphatase substrate solution (50 mM
glycine, pH 10.5, containing 1 mM magnesium chloride and 2.5 mM
p-nitrophenyl phosphate) to each well. Fifteen minutes after
addition of this aqueous substrate, the buffer was removed from the
culture and mixed with 1 ml of 1N sodium hydroxide to stop the
reaction. The absorbance of the resultant mixture at 405 nm was
then determined via spectroscopy. The level of alkaline phosphatase
activity is expressed as the level of absorbance per culture dish.
These data are shown in FIG. 22 and demonstrate that AII can
accelerate the proliferation of cells that express alkaline
phosphatase when placed in medium appropriate to induce osteogenic
differentiation.
EXAMPLE 8
Effect of Angiotensin II on Murine Lineage-Specific Cells
[0115] HPC were harvested from C57B1/6 mice by immunomagnetic
affinity chromatography and placed in semi-solid cultures with
optimal growth medium in the absence of colony stimulating factors.
At various times after initiation of culture, the formation of
colonies and the size of the colonies. (number of cells/colony) was
assessed microscopically.
[0116] Female C57B1/6 mice were purchased from Simonson and used as
a source of bone marrow cells in this study. The bone marrow was
harvested from the femur and tibia of mice by flushing with
phosphate buffered saline (PBS), pH 7.4, containing 2% fetal bovine
serum (FBS) with a 21-gauge needle. The eluant from the flushing
was centrifuged and the pellet was resuspended at 4.times.10.sup.7
nucleated cells/ml in PBS containing PBS containing 2% FBS and 5%
normal rat serum.
[0117] The reagents for immunomagnetic labeling were purchased from
Stem Cell Technologies, Inc. (Vancouver, BC). Biotin-labeled
monoclonal antibodies to the following murine lineage-specific cell
surface antigens were included in a cocktail for HPC enrichment and
used according to the manufacturer's instructions: CD5 (Ly-1),
CD45-R (B220), CD11b (Mac-1), Myeloid Differentiation Antigen
(Gr-1) and Erythroid Cells (TER 119) Ten .mu.l of antibody cocktail
was added to the bone marrow, mixed and allowed to incubate at
4.degree. C. for 15 minutes. The cells were then resuspended at
4.times.10.sup.7 cells/ml in PBS containing 2% FBS. The antibody
cocktail was then washed out and 100 .mu.l anti-biotin tetramer was
added for each ml of cells. The suspension was mixed and incubated
at 4.degree. C. for 15 minutes. Sixty ill of magnetic colloid was
then added for each ml of cells, the combination was mixed and
incubated at 4.degree. C. for 15 minutes to yield the
immunomagnetically-labeled bone marrow cells.
[0118] A column containing a stainless steel matrix was prepared by
washing the matrix with PBS followed by washing with PBS containing
2% protein. The immunomagnetically-labeled bone marrow cells were
loaded onto the column and unlabeled cell-containing medium
(enriched HPC) was collected in the flow through fraction at a flow
rate of 0.2 ml/minute. Medium was added to the top of the column so
that it did not run dry until 8 to 10 ml of enriched HPC were
harvested. Approximately 2% of the cells loaded onto the column
were isolated in the enriched HPC fractions.
[0119] The enriched HPC cell fractions were diluted into a
semi-solid medium containing 0.9% methylcellulose in alpha minimal
essential medium (alpha MEM), 30% fetal calf serum, 1% bovine serum
albumin, 10.sup.-4 M 2-mercaptoethanol, 2 mM L-glutamine, and 2%
conditioned medium. The conditioned medium was supernatant from
splenocyte cultures (1.times.10.sup.6 cells/ml) incubated for 48
hours in RPMI 1640 containing 10 .mu.g/ml pokeweed mitogen PWM),
10% FCS, and antibiotics. Various concentrations of AII, between 0
and 100;g/ml, or AII analogues or AII fragments were added in a
small volume to the wells of microtiter dishes, which contained
approximately either 3,000 cells per well or 30,000 cells per well.
The cells were incubated at 37.degree. C. and 5% CO.sub.2 for 14
days. Microscopic evaluation of the cells was performed at various
days after initiation of incubation, and the results are summarized
in FIGS. 23-33. The results clearly demonstrate that HPC colony
size increases proportionately with exposure to increased
concentrations of AII, AII analogues and AII fragments, and thus
that AII increases HPC proliferation in the absence of colony
stimulating factors.
[0120] It is to be understood that the invention is not to be
limited to the exact details of operation, or to the exact
compounds, compositions, methods, procedures or embodiments shown
and described, as obvious modifications and equivalents will be
apparent to one skilled in the art, and the invention is therefore
to be limited only by the full scope of the appended claims.
Sequence CWU 1
1
37 1 8 PRT Artificial Sequence Description of Artificial
SequenceAII 1 Asp Arg Val Tyr Ile His Pro Phe 1 5 2 7 PRT
Artificial Sequence Description of Artificial SequenceAII (2-8) 2
Arg Val Tyr Ile His Pro Phe 1 5 3 6 PRT Artificial Sequence
Description of Artificial SequenceAII (3-8) 3 Val Tyr Ile His Pro
Phe 1 5 4 7 PRT Artificial Sequence Description of Artificial
SequenceAII (1-7) 4 Asp Arg Val Tyr Ile His Pro 1 5 5 6 PRT
Artificial Sequence Description of Artificial SequenceAII (2-7) 5
Arg Val Tyr Ile His Pro 1 5 6 5 PRT Artificial Sequence Description
of Artificial SequenceAII (3-7) 6 Val Tyr Ile His Pro 1 5 7 4 PRT
Artificial Sequence Description of Artificial SequenceAII (5-8) 7
Ile His Pro Phe 1 8 6 PRT Artificial Sequence Description of
Artificial SequenceAII (1-6) 8 Asp Arg Val Tyr Ile His 1 5 9 5 PRT
Artificial Sequence Description of Artificial SequenceAII (1-5) 9
Asp Arg Val Tyr Ile 1 5 10 4 PRT Artificial Sequence Description of
Artificial SequenceAII (1-4) 10 Asp Arg Val Tyr 1 11 3 PRT
Artificial Sequence Description of Artificial SequenceAII (1-3) 11
Asp Arg Val 1 12 7 PRT Artificial Sequence Description of
Artificial SequenceAII analogue 12 Arg Xaa Tyr Ile His Pro Phe 1 5
13 7 PRT Artificial Sequence Description of Artificial SequenceAII
analogue 13 Arg Val Tyr Xaa His Pro Phe 1 5 14 3 PRT Artificial
Sequence Description of Artificial SequenceAII (6-8) 14 His Pro Phe
1 15 5 PRT Artificial Sequence Description of Artificial
SequenceAII (4-8) 15 Tyr Ile His Pro Phe 1 5 16 7 PRT Artificial
Sequence Description of Artificial SequenceAII analogue class 16
Xaa Xaa Tyr Xaa His Pro Phe 1 5 17 7 PRT Artificial Sequence
Description of Artificial SequenceAII analogue 17 Arg Val Tyr Gly
His Pro Phe 1 5 18 7 PRT Artificial Sequence Description of
Artificial SequenceAII analogue 18 Arg Val Tyr Ala His Pro Phe 1 5
19 8 PRT Artificial Sequence Description of Artificial SequenceAII
analogue 1 19 Asp Arg Val Tyr Val His Pro Phe 1 5 20 8 PRT
Artificial Sequence Description of Artificial SequenceAII analogue
2 20 Asn Arg Val Tyr Val His Pro Phe 1 5 21 11 PRT Artificial
Sequence Description of Artificial SequenceAII analogue 3 21 Ala
Pro Gly Asp Arg Ile Tyr Val His Pro Phe 1 5 10 22 8 PRT Artificial
Sequence Description of Artificial SequenceAII analogue 4 22 Glu
Arg Val Tyr Ile His Pro Phe 1 5 23 8 PRT Artificial Sequence
Description of Artificial SequenceAII analogue 5 23 Asp Lys Val Tyr
Ile His Pro Phe 1 5 24 8 PRT Artificial Sequence Description of
Artificial SequenceAII analogue 6 24 Asp Arg Ala Tyr Ile His Pro
Phe 1 5 25 8 PRT Artificial Sequence Description of Artificial
SequenceAII analogue 7 25 Asp Arg Val Thr Ile His Pro Phe 1 5 26 8
PRT Artificial Sequence Description of Artificial SequenceAII
analogue 8 26 Asp Arg Val Tyr Leu His Pro Phe 1 5 27 8 PRT
Artificial Sequence Description of Artificial SequenceAII analogue
9 27 Asp Arg Val Tyr Ile Arg Pro Phe 1 5 28 8 PRT Artificial
Sequence Description of Artificial SequenceAII analogue 10 28 Asp
Arg Val Tyr Ile His Ala Phe 1 5 29 8 PRT Artificial Sequence
Description of Artificial SequenceAII analogue 11 29 Asp Arg Val
Tyr Ile His Pro Tyr 1 5 30 8 PRT Artificial Sequence Description of
Artificial SequenceAII analogue 12 30 Pro Arg Val Tyr Ile His Pro
Phe 1 5 31 8 PRT Artificial Sequence Description of Artificial
SequenceAII analogue 13 31 Asp Arg Pro Tyr Ile His Pro Phe 1 5 32 8
PRT Artificial Sequence Description of Artificial SequenceAII
analogue 14 32 Asp Arg Val Tyr Ile His Pro Phe 1 5 33 8 PRT
Artificial Sequence Description of Artificial SequenceAII analogue
15 33 Asp Arg Xaa Tyr Ile His Pro Phe 1 5 34 8 PRT Artificial
Sequence Description of Artificial SequenceAII analogue 16 34 Asp
Arg Val Tyr Xaa His Pro Phe 1 5 35 9 PRT Artificial Sequence
Description of Artificial SequenceAII analogue 17 35 Asp Arg Val
Xaa Tyr Ile His Pro Phe 1 5 36 8 PRT Artificial Sequence
Description of Artificial Sequencep-aminophenylalanine 6 AII 36 Asp
Arg Val Tyr Ile Xaa Pro Phe 1 5 37 10 PRT Artificial Sequence
Description of Artificial Sequenceangiotensin I 37 Asp Arg Val Tyr
Ile His Pro Phe His Leu 1 5 10
* * * * *